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Abstract 
Chronic pain affects ~3 % of the world population.  Interestingly, relief can be 
achieved with botulinum neurotoxin type A (BoNT/A), which blocks 
neurotransmitter release.  An in vivo model of neuropathic pain, established in 
rat, revealed attenuation by BoNTs of chronic pain symptoms including heat 
hyperalgesia, weight bearing, mechanical and cold allodynia. 
With the long-term aim of developing a more selective therapy, a means was 
sought for producing antibodies to target Zn2+-dependent proteases of BoNT 
exclusively into sensory neurons in order to cleave and inactivate SNAREs 
[soluble NSF (N-ethylmaleimide sensitive factor) attachment protein receptors] - 
proteins essential for exocytosis.  Thus, single chain variable fragment (scFv) 
and polyclonal antibodies were generated against transient receptor potential 
vanilloid 1 (TRPV1).  scFvs obtained bound the TRPV1-A antigen but were 
unable to detect TRPV1 in transfected mammalian cells.  Rabbit polyclonal 
antibodies specific for human TRPV1 were produced, characterised and 
purified.  Encouragingly, these antibodies bound saturatably to TRPV1-
expressing cells (but not control) and got internalised, as illustrated by vesicular 
staining following stimulation with capsaicin.   
This data supports the ability of BoNT to relieve chronic pain, and the specific   
TRPV1-A antibodies produced may be applicable for future targeting of SNARE 
proteases to sensory neurons.    
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1.1. History of pain 
In the past, limited knowledge of anatomy and bodily functions meant that pain 
was not understood.  Aristotle (384-322 BC) considered the heart to be 
essential for life and the centre for feelings; however, he regarded the brain as 
unimportant.  He displayed a keen interest in sensation and believed that touch 
was linked to pain and that animals would not survive if they did not possess the 
ability to sense touch.   He considered pain to be an emotion.  An anatomical 
investigation could not be explored at the time as vivisection and dissection of 
the dead were not allowed (Perl, 2011).  Galen (130-201 AD), a physician-
philosopher of Alexandria, was able to use vivisection to oppose Aristotle’s 
views.  He believed that the brain was responsible for feeling and regarded pain 
as a sensation (Perl, 2007).  This theory was developed, by a Muslim 
philosopher and physician named Avicenna (980-1037 AD), who proposed pain 
to be an independent sensation from touch (Dallenbach, 1939).   
In the 15th century, Leonardo da Vinci, an exceptional artist, became deeply 
absorbed in science and incorporated the views of Aristotle, Galen, Avicenna 
with his own (Figure 1-1).  He dissected human corpses and arrived at the 
viewpoint that pain was a sensation that was relayed by nerves that also 
transfer information about touch (Perl, 2011).   
Many theories of pain grew from these initial findings; however, the scientific 
tools necessary to test such hypothesises were not fully established at that 
time.  The eighteenth century brought about huge advancement in conventional 
thinking from Isaac Newton and Thomas Hartley, who postulated that neuronal 
transmission were vibrations that travelled through nerves.  A more detailed 
account of the evolution of pain theories can be found in the following insightful 
articles (Perl, 2011, Perl, 2007).  Many great people have contributed to our 
knowledge of pain today and we are fortunate to possess the scientific tools 
necessary to investigate current views; however, many unanswered questions 
still remain.   
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Figure 1-1 A 15th century portrait depicting early Renaissance theories of 
sensation.   
The Aristotelian concept of the heart playing a central role is portrayed along with 
Galen’s and Avicenna’s ideas of the involvement of the nervous system.  It includes the 
five senses (vision, taste, hearing, smell and pain).  Pain induced by either noxious 
stimuli or toxin is depicted along with the transmission of pain signals through nerves.  
Image taken from Perl, 2011.           
1.2. Anatomy and physiology of pain 
1.2.1. Nociceptors 
Pain receptors (nociceptors) are free nerve endings of nerve fibres, located 
throughout the body, that convert noxious stimuli into electrical impulses and 
transfer these signals along axons (Julius and Basbaum, 2001).  First-order 
afferent nerve fibres are classified according to their type, i.e. A, B or C and are 
characterised on the basis of their structure, diameter and conduction velocities 
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(Figure 1-2).  The two types of primary afferent nociceptors include Aδ and C 
fibres.  B fibres are myelinated and transmit autonomic impulses.   Aδ fibres are 
small diameter (1-5 µm) lightly myelinated, fast conducting afferents with 
velocities of 12-30 m/s that make up ~20% of the pain afferents.  Activation of 
these fibres generates a localised ‘sharp’ immediate pain.  C fibres account for 
~ 80% of the nociceptor primary afferents, they are unmyelinated, have low 
conduction velocities (< 2 m/s), and arise from polymodal nociceptors 
(nociceptors that respond to a wide range of noxious stimuli).  Pain perceived 
by C fibres is not localised and is described as ‘dull or aching’, it usually takes 
longer for these fibres to receive input from noxious stimuli due to their lower 
conduction velocities.  Their cell bodies are positioned in the dorsal root or 
trigeminal ganglia and axons terminate in the dorsal horn of the spinal cord.   
 
Figure 1-2 Classification of nociceptors.   
a) Small (Aδ) and medium- to large-diameter (Aα, β) myelinated afferent fibres are 
found in peripheral nerves, as well as small-diameter unmyelinated afferent fibres (C). 
b) Schematic of the action potential of a peripheral nerve.   Aδ or C fibres are most 
widely expressed in nociceptors, and differ in their conduction velocities (6–25 and 
~1.0 m s–1, respectively) which represent the first (fast) and second (slow) responses to 
painful stimuli.  Image taken from Julius and Basbaum, 2001.     
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1.2.2. Neuroeffector functions 
In conditions of chronic pain, peripheral nociceptors are continually activated 
even in the absence of stimuli, usually indicative of an abnormal chemical 
processing environment.  These nociceptors release, by exocytosis, 
neuropeptides and inflammatory mediators such as substance P, calcitonin 
gene-related peptide (CGRP), brain-derived neurotrophic factor, bradykinin, 
histamine, nerve growth factor, serotonin, noradrenaline, adenosine, 
interleukins and neuropertide Y; efflux of others (nitric oxide, prostaglandins and 
H+) occurs by non-exocytotic means (Dray, 1995).  Some of these substances 
are primary activators of nociceptors, while others act secondarily by sensitising 
nerve terminals to reduce their activation thresholds.   
1.2.3. The spinal cord and transmission of signals 
The spinal cord plays a crucial role in the pain pathway as a great deal of 
information processing takes place here, especially in the dorsal horn of grey 
matter.  The spinal cord is separated incompletely into two symmetrical halves 
by the dorsal median sulcus and ventral median fissure.  A small central canal 
is located in the centre; surrounding this canal is the spinal grey matter, 
composed of nerve cell bodies, their dendrites and synaptic connections.  The 
outer region of the spinal cord contains white matter comprising of ascending 
and descending nerve fibres.  The grey matter is H/butterfly shaped; the dorsal 
horn is usually arranged into six numbered layers/laminae based on their 
Rexed’s light microscopy classification (Figure 1-3).  Pain afferents from the 
dorsal root terminate in both laminae I (marginal zone) and II (substantia 
gelatinosa).  Signals transferred from Aδ fibres are relayed to the lateral 
spinothalmic tract, travels to the ventrobasal and posterior nuclei or to the 
thalmic relay nuclei and onwards to the post central somatosensory area of the 
cerebral cortex.  Signals sent by C fibres reach the medial nucleus of the 
thalamus, and continue to the pre-frontal somatosensory region of the cerebral 
cortex.  
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Figure 1-3 Spinal cord and transmission of pain signals.   
Pain signals are propagated to the spinal cord dorsal horn via pain 
receptors/nociceptors.  Acute nociceptive pain, stimulates the release of pain mediators 
from primary afferent terminals that project to laminae I, IV and V in the spinal cord 
dorsal horn.  Aβ, Aδ and C fibres also project to laminae II–VI. Pain signals from the 
dorsal root ganglia (DRG) are sent to the dorsal spinal cord, brain stem and eventually 
to the brain, where pain is perceived.  Image taken from Milligan and Watkins, 2009.     
1.2.4. The pain gate theory 
Aβ fibres convey sensations of light touch (normally innocuous stimuli), and 
those that innervate the same segment of C fibres have the ability to inhibit C 
fibre mediated pain; this is referred to as the pain gate control theory, 
proposed by Melzack and Wall in 1965 (Melzack and Wall, 1965).  This concept 
is described as a gating mechanism in the spinal dorsal horn; firing of large C 
fibres, inhibit interneurons so that input is then transferred to the second order 
neurone, leading to pain.  Aβ fibres can reactivate the interneurone and close 
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the gate, preventing pain signals from being propagated onwards to relieve 
pain. (Figure 1-4).  
 
Figure 1-4 Schematic of the pain gate control theory. 
The gate control theory is a term used to describe the regulation of activity between 
Aβ- and C-fibres.  When C-fibre input is greater than that of Aβ-fibres, the gate opens, 
permitting activation of the second order neurone.  Aβ fibres can disinhibit the 
interneurone, closing the gate, resulting in pain control.  
1.2.5. Descending inhibitory pathways 
Descending pain modulation is controlled by various areas of the brain including 
the pariaqueuctal grey matter in the midbrain and the region surrounding the 
nucleus raphe magnus in the medulla.  The periaqueductal grey matter receives 
neuronal messages via a range of CNS sources including the thalamus, 
hypothalamus, cerebral cortex and spinal cord (Figure 1-5).  The periaqueductal 
grey matter transmits its analgesic effect by activation of the nucleus raphe 
magnus and the nearby medulla.  Pain mediating neurons containing 5-
hydroxytryptamine and noradrenaline primarily arise from the nucleus raphe 
magnus and medulla, respectively, and project from the medulla to the dorsal 
horn.   
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1.2.6. Ascending pain pathways 
Secondary pain processes project to the contralateral spinothalamic and 
spinoreticular tracts.  The spinothalamic tract comprises of fibres from laminae I 
and V of the dorsal horn that synapse in the ventrobasal thalamic nuclei.  Fibres 
from these nuclei project within the posterior region of the internal capsule to 
parts of the cerebral cortex including the somatosensory cortex.  The 
spinorecticular tract includes medial fibres from the spinothalamic tract that 
project to the nuclei in the midbrain retricular formation, the nucleus raphe 
magnus, the periaqueductal grey matter, the hypothalamus and the medial 
nuclei of the thalamus (Figure 1-5).  Projections from these regions transfer 
information to various regions of the brain such as the cortex and limbic system 
(Basbaum et al., 2009).   These two pain pathways are believed to be 
responsible for the diverse sensory features of pain.  The spinoreticular tract 
pain pathway is thought to contribute to pain intensity feedback control 
(mediated through the descending pathway), as well as affective and emotional 
aspects of pain.  However, the spinothalamic somatosensory cortex pathway is 
involved in the appreciation of special and sensory aspects of pain. 
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Figure 1-5 Schematic of spinal and supraspinal pathways of pain.   
Second-order neurons project to higher centres through the contralateral spinothalamic 
and spinoreticular tracts, which are found in the anterolateral white matter of the spinal 
cord.  Ascending nociceptive fast and slow pathways are depicted in red and green, 
respectively.  Descending inhibitory tracts are illustrated in blue.  Abbreviations; 5-HT, 
5-hydroxytryptamine, NA, noradrenaline.  Image taken from Steeds, 2009.    
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1.3. Classification of pain 
Pain may be described as an unpleasant subjective sensory experience 
initiated by noxious stimuli, inflammation or damage to the nervous system.  It 
can be further classified according to its type, with nociceptive pain being the 
most widely experienced (Figure 1-6).  Nociceptive pain is a short acting 
sensation to a noxious stimulus.  It serves a protective function, whereby high 
threshold nociceptors (sensory receptors in the peripheral nervous system) are 
activated by painful stimuli and signals are propagated from the periphery 
through the spinal cord, brain stem, and thalamus to their destinations- the 
cerebral cortex, where the sensation is perceived (Woolf, 2004).  Nociceptive 
pain is an important and essential alarm system that alerts the individual of fore 
coming danger to prevent the body from damage.  Those that have inefficient 
nociceptive control systems, including patients with congenital analgesia 
(resulting from a nerve growth factor tyrosine kinase A mutation that leads to a 
loss of high-threshold sensory neurons), have reduced life expectancies due to 
their inability to protect themselves from harmful noxious stimuli (Miranda et al., 
2002).  Acute, inflammatory pain is produced by tissue damage resulting in 
the release of peripheral inflammatory mediators to the affected inflamed area.  
The purpose of this short-term response is to encourage healing.  Following 
inflammation, the sensory nervous system adapts by lowering the nociceptor 
activation threshold, so that normally non-painful stimuli produce pain 
(allodynia) and responses to noxious stimuli are enhanced (hyperalgesia).  
Once the site of injury heals, this pain usually subsides; however, in some 
cases it may become chronic.  Maladaptive pain is unique to acute/adaptive 
pain (nociceptive and inflammatory), in this case abnormal pain processing 
continues long after the noxious stimulus is present or the injury has healed.   
Neuropathic pain may result from lesions to the peripheral or central nervous 
systems leading to alterations in plasticity and lowering of nociceptive 
thresholds to produce allodynia, hyperalgesia and secondary hyperalgesia 
(transfer of sensitivity to the non-injured area).  In contrast, dysfunctional pain 
is quite puzzling as it occurs in the absence of inflammation, lesion to the 
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nervous system or noxious stimulus, which leads to increased nociceptive 
signalling.   
Chronic (long-term inflammatory, neuropathic and dysfunctional) pain poses 
serious health implications in a range of conditions including: arthritis, multiple 
sclerosis, chronic back and shoulder, chronic migraine and myofacial pain.  A 
recent epidemiological study revealed that chronic pain affects ~ 35% of the 
Irish population, exerting huge pressures on both the economy and patient 
quality of life with 61% of subjects in one case study being unable to work 
resulting in a 19% job loss (Raftery et al., 2011).  What is even more alarming is 
the fact that the majority of those affected do not positively respond to non-
addictive treatments available on the market; additionally, analgesics prescribed 
are transient-acting, and produce undesired negative effects which leads to 
difficulties with long-term use.  Thus, there is an urgent clinical unmet need for 
efficacious, long-acting treatments to meet the requirements of chronic pain 
sufferers. 
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Figure 1-6 Classification of pain.  
Pain may be subdivided according to its type (nociceptive, inflammatory, neuropathic or 
functional/dysfunctional).  Nociceptive or inflammatory are pain produced in response 
to noxious stimuli (nociceptive) or tissue damage (inflammatory). Neuropathic is pain 
produced following lesion to the peripheral or central nervous systems, while 
dysfunctional pain is produced by increased nociceptive signalling in the absence of 
inflammation, lesion to the nervous system or noxious stimuli.  Image taken from Woolf, 
2004.     
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1.4. Mechanisms involved in chronic pain 
Chronic pain is a complex disease that involves multiple mechanisms (Figure 1-
7).  Following (peripheral) inflammation, expression of ion channels are altered, 
e.g. the transient receptor potential vanilloid type (TRPVI) channel increases, 
thereby, lowering the susceptibility to heat activation.  Alterations of K+ and Na+ 
channels increase membrane excitability so that ectopic signals are abnormally 
triggered, resulting in spontaneous pain sensations.  
 
Figure 1-7 Mechanisms involved in chronic pain.   
Damage/injury to the spinal nerve leads to changes at many levels.  This schematic 
illustrates eight different sites of pathophysiological changes. (1) At the injury site, 
spontaneous neural activity and ectopic sensitivity to mechanical stimuli occurs. (2) 
Expression of molecules in the dorsal root ganglion of the damaged nerve are 
changed.  Spontaneous neural activity initiates in the dorsal root ganglia (DRG). (3) 
The furthest region of the injured nerve undergoes Wallerian degeneration; this 
introduces the surviving nerve fibers from uninjured areas of the nerve to an 
inflammatory soup. (4) Increased trophic factors from the partly denervated tissue may 
result in sensitisation of primary afferent nociceptors. (5) The expression of various 
molecules in the dorsal root ganglion of the non-injured nerve is altered. (6) 
Sensitisation occurs in the postsynaptic dorsal horn, thus, modifying the response to 
cutaneous stimuli. (7) Activated microglial cells contributes to this sensitisation. (8) 
Changes that take place in the descending modulation of dorsal horn neurons.  
Schematic taken from: Campbell and Meyer, 2006.        
14 
 
1.4.1. Peripheral and central sensitisation 
In chronic pain, repeated stimuli reduces the threshold of nociceptive afferents 
leading to enhanced responsiveness of the peripheral terminals of nociceptors, 
this is referred to as peripheral sensitisation.  This results in normally 
innocuous stimuli being perceived as noxious.  This sensitisation is induced by 
the actions of neuropeptides and inflammatory mediators released by either 
Ca2+ regulated exocytosis such as substance P, CGRP, bradykinin, nerve 
growth factor, serotonin or neuropeptide Y or by non-exocytotic mechanisms 
(e.g. nitric oxide, prostaglandins or H+) (Dray, 1995).  Release of these above-
noted neuropeptides and inflammatory mediators amplifies the impulses 
transferred to the cell bodies of either dorsal root or trigeminal ganglia, 
producing central sensitisation (Latremoliere and Woolf, 2009, Woolf, 2011).  
These are major processes that both contribute dramatically to the hyper-
responsiveness to signalling substances. 
1.4.2. Changes in the ectopic activity of afferent neurons and 
alterations in the expression of molecules 
In chronic pain conditions, following peripheral nerve damage, spontaneous 
ectopic activity occurs in both the injured and nearby uninjured nociceptive 
afferents resulting in spontaneous pain.  Redistribution of Na+ channels are 
thought to be partially responsible for these symptoms.  Numerous other 
proteins, including voltage gated K+ channels may also play a contributory role 
in the changes to membrane excitability of nociceptive neurons.  Receptor 
proteins such as the TRP family of cation channels are also affected by this 
process.  A key member of this family includes TRPV1 which is widely 
expressed in C and Aδ fibres, TRPV1 is activated by heat and capsaicin (the 
pungent irritant found in chilli) evoking a burning painful sensation.  Following 
nerve damage, TRPV1 expression is reduced in the injured nerve but up-
regulated in the uninjured nerve.  This altered TRPV1 expression can generate 
spontaneous nerve activity in response to natural body temperature if the 
noxious heat sensor threshold is reduced.   
15 
 
1.4.3. Immune mechanisms 
Following injury, mediators are released by nociceptors or non-neuronal cells 
(e.g. macrophages, platelets, fibroblasts); these infiltrate to the site of injury to 
promote or speed healing (Figure 1-8).  In chronic pain, these substances 
remain long after the injury has healed and create an abnormal processing 
environment and may be referred to as “inflammatory soup” which includes a 
multitude of substances including; neurotransmitters (e.g. serotonin), peptides 
(e.g. CGRP, SP), lipids (e.g. prostaglandins, endocannabinoids), cytokines and 
chemokines (Basbaum et al., 2009).  This “inflammatory soup” directly 
contributes to peripheral sensitisation of nociceptors and primary afferents. 
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Figure 1-8 Components of the inflammatory soup.   
Following injury/damage, mediators are released to promote healing.  In neuropathic 
pain states, alterations of these inflammatory mediators continues long after healing 
has ceased.  These immune cells sensitise primary afferents, pain receptors and 
second order neurons to create pain hypersensitivity.  Abbreviations correspond to the 
following; 5-HT, 5-hydroxytryptamine, H+, protons, ATP, adenosine triphosphate, TrkA, 
tyrosine kinase receptor A, BK2, bradykinin receptor, 5-HT3, 5-hydroxytryptamine, 
P2X3, purinergic receptor, ASIC3, acid-sensing ion channel 3, VR1, vanilloid receptor 
1, PGE2, prostaglandin E2, CB1, cannabinoid receptor, VRL-1, vanilloid receptor 1-like 
receptor, DEG, degenerin, ENaC, epithelial sodium channel.  Image taken from Julius 
and Basbaum, 2001.       
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1.5. Current pharmacological treatments and limitations 
Unfortunately, the majority of sufferers do not respond to currently available 
non-additive medicines; also, commonly-used analgesics are short-acting, 
cause unwanted adverse effects which are a serious problem for repeated use 
in chronic pain sufferers. Hence, there is a huge unmet need for more effective 
long-acting treatments.  The current therapeutic strategy for the treatment of 
neuropathic pain generally involves a stepwise approach to determine which 
treatment or combinations most efficaciously relieve pain with the least side-
effects.  Drugs currently available include ion channel blockers, opioids and 
antidepressants (Figure 1-9).  The following articles provide a more 
compressive understanding of the pharmacological treatment options for 
neuropathic pain (Baron et al., 2010, Dray, 2008, Davis, 2007, Dworkin et al., 
2007, Markenson, 1996). 
1.5.1. Ion channel blockers 
Gabapentin and pregabalin bind to subunits of the voltage-gated Ca2+ channel 
on primary nociceptor afferents, and reduce neurotransmitter release by 
inhibiting depolarisation.  Both display similar pharmacodynamics (Sills, 2006), 
but pregabalin is better absorbed than that of its predecessor (Guay, 2005).  
They are efficacious in treating neuropathic conditions such as diabetic 
neuropathy (Wiffen et al., 2005, Dworkin and Kirkpatrick, 2005); however, the 
major limitation with these treatments is that doses need to be carefully 
adjusted to prevent kidney failure.  Lidocaine is a non-specific Na+ channel 
blocker that is generally used topically to relieve pain by inhibiting local 
excitability.  
1.5.2. Opioids 
Opioids bind to specific G-protein-coupled receptors with various affinities 
representative of their potencies.  Opioid receptors are divided into three types, 
µ, δ and κ and may be activated by either endogenous or exogenous opiate 
peptides which act as receptor agonists.  Efficacy has been achieved with 
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opioid treatment (Dworkin et al., 2007); however, the long-term side effects and 
abuse potential limit their usefulness in chronic neuropathic pain. 
1.5.3. Antidepressants 
Tricyclic antidepressants have been used to treat patients suffering from 
neuropathic pain, independent of their action on depression.  Antidepressants 
can control pain in a variety of ways including blocking; Na+ and Ca2+ channels, 
NMDA receptors and the reuptake of neurotransmitters (Sindrup et al., 2005).  
Efficacy has been found in patients with painful diabetic peripheral neuropathy 
(Hempenstall et al., 2005).  However, a majority of neuropathic pain sufferers 
do not positively respond to tricyclic antidepressants and lack of efficacy has 
been found in patients with conditions such neuropathic cancer pain 
(Mercadante et al., 2002).  Typical side effects such as fatigue and dry mouth 
also limit their usefulness (Dworkin et al., 2007). 
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Figure 1-9 Pathways and mechanisms involved in pain, including treatment 
options. 
The ascending and descending pain pathways, are illustrated in the left and right, 
respectively.  The roles of specific regions are described in yellow boxes.  Modulation 
following tissue or nerve damage are listed as well as treatment options located in red 
boxes corresponding to their action sites.  The purple arrow represents peripheral 
input.  Abbreviations correspond to the following; Am, amygdala, A5 and A7, brainstem 
nuclei containing noradrenergic neurons, CC, cerebral cortex, CN, cuneate nucleus, 
Hyp, hypothalamus, LC, locus coeruleus, NG, nucleus gracilis, NSAIDs, non-steroidal 
anti-inflammatory drugs, PAG, periaqueductal grey matter, PB, parabrachial nucleus, 
Po, posterior nuclei of the thalamus, RVM, rostro-ventral medial medulla, SNRIs, 
serotonin–noradrenaline reuptake inhibitors, TCAs, tricyclic antidepressants, VPM and 
VPL, ventrobasal thalamus, medial and lateral components (Gilron et al., 2013). 
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1.6. Botulinum neurotoxin type A as an emerging treatment 
Botox®, Allergan was first approved in 1989 in the United States for the 
treatment of strabismus, benign essential blepharospasm and conditions of the 
VIIth nerve; collective data have confirmed the safety margin of this therapeutic 
and its benefits in a range of indications.  Evidence for the potential of BoNTs in 
pain began to develop as early as the 1980’s.  A study of rodent nerve-muscle 
preparations paralysed with BoNT/A and later imaged by fluorescent immuno-
microscopy, demonstrated an accumulation of the pain mediator CGRP in the 
presynapse providing one of the first clues of its potential benefits in pain 
(Lande et al., 1989).  Supportive evidence built up as dystonia patients 
administered with intra-muscular injections of BOTOX® experienced relief of 
pain before the onset of muscle relaxation (Brin et al., 1987).  More conclusive 
clinical data was collected when people injected with BOTOX® into the forehead 
for the treatment of glabellar lines reported an improvement in the severity and 
number of migraine episodes (Binder et al., 1998).  It was initially concluded 
that BoNTs effect on pain was a secondary effect to muscle spasm.  It is now 
accepted that this interpretation is not accurate because timing and degree of 
pain relief do not completely correspond to the reduction in muscle spasms 
(Brin, 2009).  Together, these initial exciting findings stimulated a new interest 
of researchers and clinicians in BoNT as a potential anti-nociceptice.   
Clinical data further supported this hypothesis including; a double-blind, 
randomised placebo-controlled study of 30 migraine sufferers revealed that 
BOTOX® treatment of any severity was well tolerated and relieved significantly 
the frequency of migraine attacks at day 90, and the frequency of severe 
attacks at days 60 and 90 days (Barrientos and Chana, 2003).  Another double-
blind, placebo-controlled trial was performed to investigate if this bio-therapeutic 
would be suitable to treat chronic tension-type headache. All sufferers 
responded positively to local injections of BOTOX® resulting in less headaches 
and precranial muscle tenderness (Relja and Telarovic, 2004).  A further 
randomised, double-blind, placebo-controlled study of 29 patients with focal 
painful neuropathies and mechanical allodynia revealed, for the first time, that 
BOTOX® exerted direct analgesic effects in these subjects independent of its 
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role on muscle tone (Ranoux et al., 2008).  The effectiveness of this treatment 
for refractory neck pain was also investigated in a randomised, double-blind 
placebo-controlled investigation of 47 subjects assigned to either BOTOX® or 
placebo (Miller et al., 2009).  A significant decrease in the mean pain intensity 
was recorded in the treated group; a substantially larger proportion responded 
to all three outcomes compared to the placebo group.  More recently, two multi-
center double-blind, randomised, placebo-controlled trials of the PREEMPT 
(Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) clinical program 
were conducted; 1384 chronic migraine suffers were randomly allocated to 
either onabotulinumtoxinA (BOTOX®) or placebo.  The results from this large 
trial demonstrated BOTOX® to  be an effective prophylactic treatment (Dodick 
et al., 2010) as one dose significantly reduced the occurrence of headache 
days, a major benefit that lasted six months.  Following such encouraging 
results from these clinical studies, Allergan Inc. was granted approval by the 
FDA for BOTOX® as a treatment for chronic migraineuers (headaches for 15 
days or more per month) in the UK, United States and other countries; status of 
applications to other countries are pending (Aoki and Francis, 2011). 
1.6.1. Botulinum neurotoxins 
Botulinum toxin was first discovered in the blood of a patient with botulism by a 
Belgian scientist named Van Ermengem in 1897, as a product of Clostridium 
botulinum and the agent responsible for botulism food poisoning (Schantz and 
Johnson, 1997).  BoNTs are a class of homologous di-chain proteins (serotypes 
A-G), possessing unique characteristics, from Clostridium botulinum  whose 
active form consists of a Zn2+-dependent proteolytic light chain (LC; Mr ~50k) 
joined by a disulphide and non-covalent bonds to a heavy chain (HC; Mr ~100k) 
(Figure 1-10).  All toxin serotypes block acetylcholine release at the peripheral 
cholinergic nerve endings, producing temporary denervation and muscle 
relaxation. The action of BoNT involves a number of important steps including; 
1. Binding to neuronal ecto-acceptors via the C-terminal half of the HC (HC), 2. 
Endocytosis of the toxin mediated by its HC N-terminal moiety (HN) and 3. 
Translocation of the LC into the cytosol (Figure 1-11).  This leads to blockade 
of Ca2+-regulated exocytosis of transmitters and all mediators by the cleavage 
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of SNAREs which are responsible for vesicle fusion with the plasmalemma 
(Meng et al., 2007).  Serotypes differ in their target SNAREs; BoNT/A, C1 and 
BoNT/E cleave SNAP-25 by removing 9, 8 and 26 amino acids residues from 
the C-terminus of SNAP-25, respectively. The light chains of the remaining 
BoNT serotypes cleave syntaxin (BoNT-C1) and synaptobrevn (BoNT-B, BoNT-
D, BoNT-F and BoNT-G) (Dolly, 2003).  SNARE cleavage inactivates the 
proteins and disturbs the normal functioning of the SNARE complex, inhibiting 
exocytosis.  BoNT/A is the most widely used clinically and the most toxic 
serotype.  BoNT/A has been shown to block acetylcholine release from gamma 
motor neurons that innervate the intrafusal fibres in muscle spindles; this may 
change secondary feedback and assist in pain relief (Rosales et al., 1996).  
However, the direct actions of BoNT on the release of pain mediators is 
believed to play an important role in its therapeutic effect (Aoki, 2005). 
 
Figure 1-10 Structure of BoNT/A.  
BoNTs are cleaved by proteases into their active form composed of a ~50 K light chain 
and a ~100 K heavy chain linked by a disulphide and non-covalent bonds.  The HC 
region is responsible for binding, the HN for translocation and the LC for protease 
activity.  Image taken from Dolly and O'Connell, 2012.       
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Figure 1-11 Mechanism of action of BoNT/A at the neuromuscular junction.  
A) Illustrates normal neurotransmitter release at the neuromuscular junction (NMJ). B) 
The steps involved in BoNT/A endocytosis at the NMJ, including cell surface binding, 
vesicle internalisation, translocation of the LC protease into the cytosol, and proteolytic 
cleavage of the requisite SNARE.  This results in inhibition of neurotransmitter release. 
BoNT/A cleaves SNAP-25. Abbreviations; BoNT-A, botulinum neurotoxin serotype A, 
H+, protons, Ach, acetylcholine, SNAP-25, synaptosomal-associated protein 25, VAMP, 
vesicle-associated membrane protein.  Image taken from Robertson and Garza, 2012.    
1.6.2. A hypothetical mechanism of action for pain relief by BoNT/A 
The hypothesised anti-nociceptic mechanism of action of BoNT/A has been 
described in the following article (Aoki and Francis, 2011): 
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1. Administration of BoNT/A directly and acutely blocks the release of pain 
neurotransmitters at the periphery leading to a reduction in peripheral 
sensitisation and an alleviation of pain. 
2. Reduction of peripheral sensitisation decreases the signals propagated to 
the central nervous system and, in turn, indirectly reduces central 
sensitisation. 
 
Figure 1-12 Hypothesised mechanism of action of BoNT pain relief by /A. 
A) Neuropeptides and inflammatory mediators are secreted following application of 
painful stimuli or injury, generating peripheral sensitisation. This increases the signals 
propagated to cell bodies in both the dorsal root and trigeminal ganglia, producing 
central nervous system sensitisation. Abbreviations refer to the following; Glu, 
glutamate; Sp, substance P; CGRP, calcitonin gene related peptide; NGF, nerve 
growth factor; BDNF, brain derived neurotrophic factor. B) The actions of BOTOX® on 
sensitisation. Treatment with the toxin inhibits the exocytotic release of 
neurotransmitters and pain mediators; as a result, peripheral sensitisation is blocked 
directly and central sensitisation indirectly. Figure taken from Dolly and O'Connell, 
2012.     
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1.7. Project aims 
 To adopt the spinal nerve ligation model of chronic pain in the rat 
 To optimise and validate the chronic pain model 
 To evaluate the efficacies of BoNT-based therapeutics in vivo 
 To develop and characterise polyclonal and scFv antibodies to a prime 
pain target for future targeting of BoNT-based proteases exclusively to 
sensory neurons  
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2. MATERIALS AND METHODS 
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2.1. Materials 
2.1.1. Antibodies/markers 
 
Item 
 
1O/2O 
Ab 
 
Catalogue 
number 
 
Supplier 
 
Species 
raised 
in 
 
WB 
dilution 
 
IHC 
dilution 
Anti-rat TRPV1 
(extracellular)-
ATTO-488 
Synthetic 
peptide: 
(C)NSLPMEST
PHK*SRGS, 
corresponding 
to amino acid 
residues 605-
619 of rat 
TRPV1 with 
replacement of 
cysteine 616 
(C616) with 
serine. 
3rd extracellular 
loop. 
1O ACC-029-AG Alomone 
Labs Ltd. 
Rabbit N/A 1:50 
Anti-rat TRPV1 
(extracellular) 
polyclonal  
(C)NSLPMEST
PHK*SRGS,  co
rresponding to 
amino acid 
residues 605-
619 of rat 
TRPV1 with 
replacement of 
cysteine 616 
(C616) with 
serine. 
3rd extracellular 
loop. 
1O ACC-029 Alomone 
Labs Ltd. 
Rabbit 1:200 1:100 
Anti-human 
TRPV1 
(extracellular) 
polyclonal 
Synthetic 
1O N/A 
Produced in-
house 
N/A 
Produced 
in-house 
Rabbit 3 µg/mL 10 µg/mL 
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peptide: 
SLPSESTSHR
WRGPAC,  corr
esponding to 
amino acid 
residues 606-
621 of human 
TRPV1.  
Anti-TRPV1 
monoclonal 
Synthetic 
peptide: 
YTGSLKPEDAE
VFKDSMVPGE
K, 
corresponding 
to C terminal 
amino acids 
817-838 of Rat 
Vanilloid 
Receptor 1. 
1O AB10295 Chemicon Guinea 
Pig 
1:1000 N/A 
Anti-FLAG® M2 
monoclonal 
antibody 
2O F3165 Sigma-
Aldrich, 
Ireland 
Mouse 0.5–10 
µg/mL 
20 µg/mL 
Anti-mouse-
Alexa-488 
2O A21121 Bio-
Sciences 
Ireland 
Ltd. 
Goat 1:500 N/A 
Anti-rabbit-
Alexa-568 
2O A11011 Bio-
Sciences 
Ireland 
Ltd. 
Goat 1:500 N/A 
Anti-rabbit-HRP 2O 711-035-152 Jackson 
Immuno 
research 
Europe 
Ltd. 
Donkey 1:5000-
10000 
N/A 
Monoclonal anti-
FLAG® M2-CY3 
2O A9594 Sigma-
Aldrich, 
Ireland 
Mouse N/A 1-10 
µg/mL 
Table 2-1 Primary and secondary antibodies. 
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2.1.2. Reagents 
Item Catalogue 
number 
Supplier 
3 M Sodium Acetate, pH 5.5 71196 Sigma Aldrich Ireland Ltd. 
3,3’-N-epsilon-Maleimidocaproic acid 
hydrazide-TFA; solid 
22106 Fisher Scientific Ireland 
Benzonase Nuclease  E1014 Sigma Aldrich Ireland Ltd. 
Capsaicin M2028 Sigma Aldrich Ireland Ltd. 
Chloroform C2432 Sigma Aldrich Ireland Ltd. 
Collagenase type 1a C9891 Sigma Aldrich Ireland Ltd. 
Corning® cell culture 25 cm2 flasks CLS3289 Sigma Aldrich Ireland Ltd. 
Corning® cell culture 75 cm2 flasks CLS3290 Sigma Aldrich Ireland Ltd. 
Cytosine-β-D-arabinofuranoside (Ara-C) C1768 Sigma Aldrich Ireland Ltd. 
Dispase type II D4693 Sigma Aldrich Ireland Ltd. 
Gibco® DMEM 
 GibcoBRL 
Ellman’s reagent 1008-6113 Fisher Scientific Ireland 
Freund’s adjuvant complete F5581 Sigma Aldrich Ireland Ltd. 
Freund’s adjuvant incomplete F5506 Sigma Aldrich Ireland Ltd. 
Immobilon Western Chemiluminescent 
HRP Substrate 
WBKLS0100 Merck Millipore 
ImmobilonTM PVDF membrane, 0.45µm IPVH00010 Merck Millipore 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
I5502 Sigma Aldrich Ireland Ltd. 
Laminin L2020 Sigma Aldrich Ireland Ltd. 
Miris TransIT-LTI  MIR 2300 Mirus Bio LLC. 
NGF 7S N0513 Sigma Aldrich Ireland Ltd. 
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Ni-NTA superflow resin 30410 Qiagen Ltd. 
Nunc Maxisorp ELISA plates flat bottom 442404 Bio-Sciences Ltd. 
PD10 desalting columns 54805 Sigma Aldrich Ireland Ltd. 
Poly-L-lysine P4832 Sigma Aldrich Ireland Ltd. 
Propan-2-ol I9516 Sigma Aldrich Ireland Ltd. 
Protein A-Sepharose® from 
Staphylococcus aureus 
P3391 Sigma Aldrich Ireland Ltd. 
RNAase-free water W4502 Sigma Aldrich Ireland Ltd. 
RNAlater® R0901 Sigma Aldrich Ireland Ltd. 
SuperscriptIII RT-PCR (kit) 18080-051 Bio-Sciences Ltd. 
Thrombin, restriction grade 69671-3 Merck Chemicals Ltd. 
TMB ELISA substrate 2023 Bio-Sciences Ltd. 
Traut’s reagent 2-iminothiolane 
hydrochloride 
1068-8644 Fisher Scientific Ireland 
Trizol 15596-026 Bio-Sciences Ltd. 
Table 2-2 Reagents used for immunisation, RNA extraction, cell culture, protein 
expression and purification and chemical conjugation. 
2.2.   Methods 
2.2.1.   Botulinum neurotoxins 
Experiments involving recombinant BoNTs were approved by the Irish 
Environmental Protection Agency and were performed under a strict set of 
safety guidelines (containment level 2).  Recombinant toxins used in these 
studies were constructed by Dr. Jiafu Wang and expressed, purified and 
activated, as previously described (Wang et al., 2011).   
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2.2.2. Antibody production and conjugation 
2.2.2.1. Selection of peptides 
Two peptides were selected corresponding to either end of the extracellular 
loops of human TRPV1 (Table 2-3).   TRPV1-A or B peptides were synthesised 
and conjugated to either BSA or KLH commercially by Anachem Ltd., UK.  The 
free peptide was used as a control for blocking and for competition experiments, 
while the TRPV1-KLH peptide was used for screening.  
Peptide Epitope Amino acids Peptide sequence 
TRPV1-A Human TRPV1 606-621 SLPSESTSHRWRGPA 
TRPV1-B Human TRPV1 637-649 ELFKFTIGMGDLE 
Table 2-3 Epitopes chosen from the hTRPV1 protein sequence for immunisation. 
2.2.2.2. Immunisation 
Rabbits were immunised with ~ 30 µg of TRPV1-A and -B peptides conjugated 
to BSA, prepared in sterile filtered PBS, with an equal volume of complete 
Freund’s adjuvant added to the final mixture.  This was subsequently vortexed 
until visibly dissolved.  Boosts consisted of ~ 8 µg of TRPV1-A and –B BSA, 
prepared in PBS in the presence of an equal volume of incomplete Freud’s 
adjuvant.  Each solution was injected subcutaneously using a 25G needle.  A 
pre-bleed was taken the day before the first immunisation and subsequent 
bleeds were taken 7 days after each boost.  Each test bleed was centrifuged at 
680 x g for 20 mins at 4OC and serum extracted were stored at -20OC for 
analysis. 
2.2.2.3. Enzyme-linked immunosorbent assays (ELISA)  
Nunc plates were coated overnight with 2 µg/ml of either TRPV1-A or TRPV1-B 
peptides conjugated to KLH.  Plates were blocked with 200 µl of 5 % milk 
marvel for 1 hr in PBS.  Serial serum dilutions were prepared in PBS with 0.1 % 
tween 20 (PBST) with 5 % milk marvel; 100 µl of each serial dilution was added 
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to the plate and incubated for 1 hr at room temperature.  Following incubation, 
plates were washed 3 times in both PBST and PBS.   Donkey-α-rabbit HRP 
secondary antibody (1:1000) in PBST with 5% BSA was added to each well and 
incubated for 1 hr at room temperature.  This was followed by 3 washes with 
PBST and PBS.  TMB (3,3’,5,5’-tetramethylbenzidine) was added to each well 
and the reaction monitored.  The reaction was stopped with 1M HCL (50 µl)/well 
and the plate was read on a Tecan plate reader at 595 nm.  
2.2.2.4. RNA extraction 
The spleen of rabbit was removed and placed in RNAlater solution (Sigma 
Aldrich, Ireland) in an RNase-free tube.  This was centrifuged for 10 mins at 680 
x g and RNAlater solution was removed;  10 mL of Trizol was added to the 
sample on ice and homogenised by sonication with power output of 50 % for 1 
min or until the whole spleen was homogenised.  The sample was allowed to 
stand at room temperature for 5 mins before being centrifuged at 595 x g for 10 
mins at 4OC.  The supernatant was carefully removed and transferred to a clean 
RNase-free tube; 3 mL of chloroform was added, mixed briefly for ~ 15 seconds 
with a vortex and incubated for 15 mins at room temperature.  Then, the 
solution was centrifuged at 12,000 x g for 15 mins.  The upper, aqueous layer 
was carefully removed and transferred to a clean tube; 15 mL of propan-2-ol 
was added to this, vortexed for 15 seconds and the solution allowed to stand at 
room temperature for 10 mins.  This was centrifuged at 12,000 x g for 15 mins 
at 4OC or until a pellet was visible.  The supernatant was carefully removed and 
10 mL of 75 % v/v ethanol was added and centrifuged at 12,000 x g for 10 mins 
at 4OC.  The supernatant was removed and the pellet allowed to air-dry for a 
few mins; 250 µl of RNAase-free water was added and gently mixed to ensure 
that the RNA went into solution.  The RNA was stored on ice, quantity was 
determined using the nanodrop, and was aliquoted and stored at – 80oC.   
2.2.2.5. Cloning 
Cloning was carried out by Dr. Arman Rahman.  Table 2-3 details the list of 
primers for this work and Figures 2-1 and 2-2 illustrate the vector maps for 
pSang4 and pSang10.  
33 
 
Location Name Sequence 
5’ end of VH RABVH1a1Nco 
RABVH1a2Nco  
RABVH1a2Nco 
RABVHX32Nco 
RabVH1Sfi   
GCCCAGCCGGCCATGGCT CAG TCG GTG GAG 
GAG TCC GGG GGT CGC CTG  
GCCCAGCCGGCCATGGCT CAG TCG GTG GAG 
GAG TCC GAG GGA GGT CT 
GCCCAGCCGGCCATGGCT CAG TCG GTG GAG 
GAG TCC GGG GGA GAC CTG  
GCCCAGCCGGCCATGGCT GAG CAG CTG AAG 
GAG TCC GGG GGA GGC CTG  
CCT TTG GTT GTT CCT TTC TAT GCG GCC CAG 
CCG GCC ATG GCT 
3’ end of VH RabJHXho TGGAGCCTTAGGCGCGCCACTCGAGACGGTGACC
AGGGTGCCTGGGCC 
5’ end of V 
kappa 
RABVK1Nhe   
RABVK2Nhe 
RABVK3Nhe 
RABVK4Nhe 
RABVK5Nhe 
RABVK6Nhe 
RABVK7Nhe  
CAACCTGCAATG GCTAGC GAT GTC GTG ATG 
ACC CAG ACT CCA TCC 
CAACCTGCAATG GCTAGC GAT GTC ATG ATG 
ACC CAG ACT CCA TCC 
CAACCTGCAATG GCTAGC GAC CCT RTG CTG 
ACC CAG ACT GCA TC 
CAACCTGCAATG GCTAGC GCA GCC GTG CTG 
ACC CAG ACA CCA TCG 
CAACCTGCAATG GCTAGC GCC CAA GTG CTG 
ACC CAG ACT CCA GCC 
CAACCTGCAATG GCTAGC GCC CTT GTG ATG 
ACC CAG ACT CCA TCC 
CAACCTGCAATG GCTAGC GCT CAA GTG CTG 
ACC CAG ACT GAA TC 
3’ end of V 
kappa 
rabKJ1Not 
rabKJ2Not 
rabKJ3Not 
rabKJ4Not 
rabKJ5Not 
TTTGTAGTCCAGTGCGGCCGCTTTGATTTCTACCT
TGGTGCCAGCTCCAAA 
TTTGTAGTCCAGTGCGGCCGCTTTGACCACCACCT
CGGTCCCTCCGCCGAA 
TTTGTAGTCCAGTGCGGCCGCTTTGATTTCCAGTT
TGGTCCCTGGGCCAAG 
TTTGTAGTCCAGTGCGGCCGCTTTGATCTCCACCA
TGGTCCCTGAGCCAAA 
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TTTGTAGTCCAGTGCGGCCGCTTTGATCTCCAGCT
TGGTCTCCTCGCCAAA 
3’ end of V 
constant 
RabKCNot TTTGTAGTCCAGTGCGGCCGCGTCACCCCTWTTG
AAGCTCTGGACGA 
W = A/T 
3’ end of V 
constant 
incorporating 
cys constant 
CysRabKNot W = A/T 
TTTGTAGTCCAGTGCGGCCGCGCAGTCACCCCTW
TTGAAGCTCTGGACGA 
 RABHKSfi GTT CCT TTC TAT GCG GCC CAG CCG GCC ATG 
GCT G 
Allows extension of all VH primers to incorporate sfi 
site 
Table 2-4 Primers that were used for amplification of rabbit VH and VLs. 
 
Figure 2-1 pSang4 vector map.  Source: John McCafferty Cambridge University. 
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Figure 2-2 pSang10 vector map.  Source: John McCafferty Cambridge University. 
2.2.2.6. Bio-panning and phage display 
Bio-panning and phage display were performed by Dr. Arman Rahman.  
2.2.2.7. Expression of scFv clones in E. coli 
Each scFv clone was seeded onto a 2TY agar plate containing glucose plus 
kanamycin and grown overnight at 37OC.  From each of these plates, a single 
colony was picked and seeded into a 5 mL starter culture (2TY medium, 2 % 
glucose, 100 µg/mL kanamycin) and grown overnight at 30OC.  A 1:1000 
dilution of each of these starter cultures was inoculated into 2TY medium 
containing 2 % glucose and 100 µg/mL of kanamycin.  This was grown until an 
Abs 600 of 0.6-0.8 was reached; temperature was reduced to 22OC and 1 mM 
of IPTG was added to induce the culture, which was grown overnight for a 
further 16-20 hrs.   
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2.2.2.8. Cell lysis 
2.2.2.8.1. Periplasmic cell lysis 
Cultures were centrifuged at 12,000 x g for 30 min at 4OC; supernatants were 
discarded and cell pellets allowed to air dry.  To the cell pellets, ice cold TES 
lysis buffer (30 mM Tris-HCL, 20 % sucrose, pH 8.0) and protease inhibitor 
(Benzonase 25 U/mL) were added, resuspended and allowed to stand on ice for 
10 min.  TES 20 % lysis buffer solution was added containing protease inhibitor 
(Benzonase 25 U/mL) and 1 M MgSO4; and the resuspension was placed on a 
roller at 4OC for a further 40 min.  The solution was transferred to a clean 
nalgene tube and centrifuged at 40,000 x g in an ultracentrifuge for 40-50 min.  
A sample of the clarified lysate was collected for analysis on SDS-PAGE and 
the remaining supernatant was purified as described in 2.2.2.9.1. 
2.2.2.8.2. Whole cell lysis 
Cultures were centrifuged as described in 2.2.2.8.1 and resuspended 
thoroughly in the following lysis buffer (150 mM NaCl, 150 mM HEPES, 1 mM 
PMSF, 2 mg/mL lysosome); the resuspended solution was placed on a roller at 
4OC for 40 min.  The solution was then freeze/thawed- placed in a - 80OC 
freezer for 1 hr and thawed in a 20OC waterbath.  The solution was then 
centrifuged at 47,900 x g in an ultracentrifuge for 45 min at 4OC.  An aliquot of 
the clarified supernatant was collected for analysis on SDS-PAGE and the 
remaining was purified as described in 2.2.2.9.1. 
2.2.2.9. Purification 
2.2.2.9.1. Purification of scFv antibodies 
scFv antibodies were purified by IMAC. Briefly, 2 mL of superflow Ni-NTA resin 
was added to a commercial 20 mL column and washed with equilibration buffer 
(20 mM HEPES, 150 mM NaCl, pH 8.0).  The clarified supernatant was mixed 
with equilibration buffer at a 1:1 ratio and incubated with the resin for 1 hr at 
4OC on a roller.  Following binding, the mixture was placed back into the column 
and the flow through collected and stored on ice.  The resin/bound scFv was 
washed three times with wash buffer (equilibration buffer plus 5 mM imidazole).  
37 
 
Bound scFv was eluted in 8-10 fractions with one bed volume 2 mL of elution 
buffer per fraction (20 mM HEPES, 150 mM NaCl, 500 mM imidazole).  The 
eluted fractions were buffer exchanged into PBS using a PD10 column, 
following standard guidelines.  Concentrations of the eluates were determined 
by Bradford assay as per commercial guidelines using a range of BSA 
standards to construct a standard curve.  Samples from each of the IMAC 
stages were separated by SDS-PAGE and protein stained as described in 2.5.1 
and 2.5.2.  Purified and buffer exchanged fractions were stored at - 20OC  
2.2.2.9.2. Purification of polyclonal α-hTRPV1 serum   
Polyclonal serum was purified by Protein-A-Separose fast flow resin from 
Staphylococcus aureus (Sigma Aldrich, Ireland). To a commercial column, 2 mL 
of Protein A resin was added and washed with ~ 10 bed volumes of wash buffer 
(Tris-HCL, pH 8.0).  In the meantime, polyclonal serum was allowed to thaw on 
ice and subsequently centrifuged at 680 x g for 20-30 mins to remove any 
debris.  Polyclonal serum was then diluted 1:1 with 1xTBS, applied to the beads 
and placed on a roller at 4OC for 1 hr to allow binding.  Following binding, the 
solution was allowed to flow through the column, was collected and stored on 
ice.  The column was washed with 10 bed volumes of wash buffer (100 mM 
Tris-HCL, pH 8.0).  The bound IgG antibodies were eluted with elution buffer 
(0.1 M of glycine, pH 3.0) into a tube containing one tenth of the bed volume of 
neutralisation buffer (1 M Tris-HCL, pH 9.0).  The pH of the combined elution 
and neutralisation buffers were first assessed before antibody elution to ensure 
that the pH was within the desired range ~7.4. Concentrations of eluted 
samples were determined by standard Bradford assay and fractions containing 
protein were pooled and buffer exchanged into PBS on PD10 columns.  
Concentration of the buffer exchanged sample was reassessed as described 
above and samples from each of the purification steps were separated by SDS-
PAGE and protein stained as described in 2.5.1 and 2.5.2.  Buffer exchanged 
purified fractions were stored at - 20OC 
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2.2.2.10.  Conjugation of anti-human TRPV1 IgG antibodies to the LC-HN-
HCN/A 
Conjugation of the LC-HN-HCN/A (comprised of the light chain, translocation 
domain and N-terminal heavy chain of BoNT/A, but lacking the binding domain) 
to the Fc portion of the antibody was attempted by oxidation of the 
carbohydrates present in the Fc region with periodic acid (from sodium 
metaperiodate) to form reactive aldehyde groups on the antibody. These groups 
react with hydrazides at low pH ranges of 5-7 to form hydrazone bonds.  Traut’s 
reagent was used to introduce free sulfhydryls into the LC-HN-HCN/A.  A 
heterobifunctional crosslinker, namely 3,3’-N-[e-maleimidocaproic acid] 
hydrazide trifluroacetic acid salt (EMCH), containing a reactive sulfhydryl and 
hydrazide group was reacted with the LC-HN-HCN/A. The maleimide group 
reacts with the sulfhydryl group present in the LC-HN-HCN/A and the hydrazide 
group reacts with the oxidised antibody, together these reactions should form 
the antibody-LC-HN-HCN/A conjugate. 
2.2.2.11.  Screening of TRPV1 antibodies 
Lysates from HEK WT cells and HEK cells over-expressing human TRPV1 were 
separated by SDS-PAGE (as detailed below in 2.5.1).  Following transfer of the 
proteins onto PVDF membranes, any non-specific binding of the membranes 
were blocked by BSA; membranes were then incubated with equal volumes of 
the crude cell lysates in blocking buffer overnight at 4OC.  Membranes were 
then washed thrice in TBST and incubated for 1 hr in secondary antibody 
(donkey-anti-rabbit-HRP 1:5000).  Membranes were subsequently rewashed 
thrice and developed using a chemilluminance method of detection and 
visualised in a G-BOX.  
2.3. Cell culture 
2.3.1. Dorsal root ganglia- neuronal dissection and primary culture 
DRGs were dissected from P3-P5 rat pups.  Briefly, the spinal cord was 
removed, opened along the middle and carefully pushed back to allow clear 
visibility of the ganglia.  These were removed using a 45o angled forceps, 
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dissociated and cultured similarly to the method of Malin et al., 2007 with the 
following modifications.  The ganglia were washed once in ice-cold DMEM and 
incubated with shaking at 37OC for 30 min with 2.4 U/mL and 1 mg/mL of 
dispase II and collagenase I.  Cells were triturated and plated onto glass 
coverslips pre-coated with poly-L-lysine and laminin 0.1 mg/mL and 20 µg/mL.  
Cells were cultured in DMEM containing 10 % (v/v) foetal bovine serum, 100 
U/mL penicillin, 100 µg/mL streptomycin plus 50 ng/mL 2.5s NGF, and 
maintained in a humidified atmosphere at 5% CO2 and 37OC.  Half of the 
medium per well was replaced with medium containing Ara-C (10 µM) from 
days 1-5 and complete medium was added every second to third day thereafter. 
2.3.2. Culture of human embryonic kidney cells 
HEK293 cells were maintained in DMEM (supplemented with 10% fetal bovine 
serum, streptomycin, penicillin and L-glutamine). The cells were transiently 
transfected with pcDNA3 encoding either human or rat TRPV1 according to the 
transfection reagents recommended guidelines using a 3:1 ratio of the Miris 
TransIT-LTI transfection reagent to DNA.  
2.4. Immunocytochemistry and quantification 
2.4.1. Immunocytochemistry 
2.4.1.1. Permeabilised cell staining 
HEK293 cells WT and those transiently transfected with TRPV1 were washed 
with PBS and fixed for 20 min at room temperature with 3.7% PFA.  Non-
specific binding sites were blocked with 1% BSA in PBS; 0.25% Triton X-100 
was added to allow permeabilisation for 30 min at room temperature.  
Subsequently, cells were incubated overnight at 4OC with varying 
concentrations of the purified anti-human TRPV1 rabbit primary antibodies in 
blocking buffer.  This was followed with three washes in PBS, and 1 hr 
incubation at room temperature with an Alexa-conjugated goat anti-rabbit IgG 
secondary antibody (1:500) prepared in PBS with 10% goat serum. 
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2.4.1.2. Staining of intact cells 
Staining of non-permeabilised cells was carried out similarly to section 2.4.1.1 
with the following modifications. Cells were not fixed prior to incubation and the 
primary antibody was prepared in blocking buffer without Triton X-100.  
Following incubation with primary antibody, the cells were fixed, permeabilised 
and incubated with secondary antibody as above. 
2.4.1.3. Basal and stimulated uptake of the TRPV1 antibody  
For basal uptake experiments, α-hTRPV1 rabbit antibody 10 µg/mL was applied 
to HEK cells in complete medium (DMEM supplemented with 10% fetal bovine 
serum, streptomycin, penicillin and L-glutamine) for various times in a 
humidified atmosphere at 5% CO2 and 37OC.  Following incubation with the 
primary antibody, cells were washed, fixed, permeabilised and incubated in 
secondary antibody prepared in blocking buffer as described above.  For 
stimulated uptake antibody experiments, 1 µM of capsaicin was applied.  
2.4.1.4. Internalisation of the anti-human TRPV1 antibody 
For assay of internalisation, staining was carried out similarly as for basal 
uptake.  Concentrations used include: 1 µM of capsaicin, 6 µg of filipin, 100 nM 
of bafilomycin A1.  
2.5. Protein assays 
2.5.1. SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to separate proteins on the basis of size with SDS detergent being added 
to remove any secondary or tertiary structures.  Proteins were loaded onto 
manually prepared acrylamide gels and run with 1 x electrophoresis buffer (1 
litre: 25 mM Tris, 129 mM glycine, 0.1% SDS) at 120 volts (stacking) and 170 
volts (resolving gel) until proteins were separated according to their sizes, 
corresponding to the pre-stained protein marker.     
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2.5.2. Coomassie Blue staining 
Gels were prepared as per 2.5.1 and placed in heated 0.25% Coomassie 
brilliant blue G 250 (made up with 10% acetic acid and 45% methanol) for 1 hr 
on a shaker.  Gels were then washed once with distilled H20 and placed in 
destain (10 % acetic acid plus 30% methanol) until the bands were clearly 
visible. 
2.5.3. Western blotting 
Following SDS-PAGE as per 2.5.1, a piece of PVDF membrane with a 0.45 µm 
pore size (Millipore) was soaked briefly in methanol (30 sec), rinsed once with 
deionised water and placed in transfer buffer (1 Litre: 25 mM Tris-base, 190 mM 
glycine, 10% methanol in dH2O).  The sponge and filter paper were also soaked 
in transfer buffer and assembled as follows: sponge, filter paper, PVDF 
membrane, protein gel, filter paper and sponge.  This cassette was tightly 
sealed with the membrane side facing towards the positive electrode and 
carefully placed in a transfer tank for 3-4 hrs at 45 volts at 4OC (TE62, Hoefer. 
Inc.).  Following transfer, the membrane was blocked for 1 hr at room 
temperature in either 5% BSA/milk marvel in TBST (0.1% Tween 20 in TBS).  
The membrane was then incubated with primary antibody in blocking buffer for 
1 hr at room temperature.  Membranes were then washed with 3 x 10 min 
washes in TBST and incubated for 1 hr in a horseradish peroxidise conjugated 
anti-species secondary antibody again in blocking buffer.  The membrane was 
washed as described above, proteins were visualised by ECL reagent, images 
grabbed with a G-BOX and quantified by densitometric analysis using Image J 
software. 
2.5.4. Determination of protein concentration by Bradford assay 
Concentrations of proteins were determined by Bradford assay, as per 
commercial guidelines, using a standard curve of BSA.  
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3. ESTABLISHMENT OF AN IN VIVO MODEL OF CHRONIC 
PAIN TO EVALUATE THE EFFICACIES OF RECOMBINANT 
BoNTs 
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3.1. Background 
3.1.1.  Evidence for the efficacy of BoNTs in the treatment of 
pain in vivo 
Strong evidence supports the ability of Botox® to attenuate signalling in animal 
models of inflammatory pain induced by formalin ((Luvisetto et al., 2006, Aoki, 
2003, Cui et al., 2004) or capsaicin ((Wang et al., 2011, Bach-Rojecky and 
Lackovic, 2005) and neuropathic pain ((Park et al., 2006, Bach-Rojecky et al., 
2005, Bach-Rojecky et al., 2010, Marinelli et al., 2010).  However, further pre-
clinical studies are required to fully elucidate the anti-nociceptive mechanism of 
BoNTs and, particularly, to assess the therapeutic potential of newly engineered 
variants.  Neuropathic pain studies of BoNT/A are summarised in Table 3-1. 
Ref. Park et el., 2006 Bach-Rojecky et 
al., 2005 
Luvisetto et al., 2007 
Species Rat  Rat  Mouse 
Strain SD Wistar CD1 
Pain model SNL- L5 & L6 
Neuropathic Pain 
Partial sciatic nerve 
transaction 
Neuropathic Pain 
Chronic constriction 
injury (CCI) 
Neuropathic pain 
Treatment BoNT/A BoNT/A BoNT/A 
Vehicle Saline Saline Saline 
Day of drug 
administration 
7 days recovery 
after surgery 
Two weeks 
following surgery 
3 days before CCI 
and 5 or 12 days after 
CCI 
Route of 
administration 
Intra plantar (40 µl) Peripheral injection Intra plantar 
Units. 10, 20, 30 or 40 
U.kg-1 
7  U.kg-1 (20 µl of 0.005 nM, in 
0.9% NaCl; 
corresponding to 15 
pgtox /mouse per 
paw) 
Time of testing 
post treatment 
24 hrs 24 hrs 24 hrs 
Behaviour 
tests selected 
Mechanical, cold 
allodynia (100% 
Acetone) & rotarod) 
Hot plate test, 
Randall and Selitto 
Mechanical allodynia 
Days of testing 0, 1, 3, 5, 7, 15 0, 1, 5, 15, 30 - 
Study duration 21 days  50 days  90 days 
Table 3-1 Literature survey of the efficacy of BoNT/A in neuropathic preclinical 
pain models. 
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3.1.2.  Inflammatory pain models 
3.1.2.1. Formalin-induced pain model 
The formalin-induced inflammatory pain model was initially created to screen 
the anti-nociceptive efficacies of analgesics (Dubuisson and Dennis, 1977). It 
involves intraplantar injection of formaldehyde (formalin) into the rat paw, which 
subsequently elicits pain related-behaviour, such as licking/biting and 
shaking/flinching (Wheeler-Aceto et al., 1990).  Pain responses of this model 
occurs in two phases, namely phase I and phase II; the former is an acute stage 
which lasts approximately 10 mins, followed by a short rest period and, finally, 
an extended phase.   Pre-treatment with BoNT/A complex dose-dependently 
abolished the symptoms of formalin-induced behaviour during phase II, but not 
phase I (Cui et al., 2004). Each stage reflects different physiological 
mechanisms; stage I is triggered by nociceptor activation by peripheral stimuli, 
whereas II is dependent on inflammation and spinal cord sensitization (Puig and 
Sorkin, 1996). This suggests that BoNT/A does not exert a localised analgesic 
effect but probably reduces central sensitization (Dolly and Aoki, 2006). When 
different BoNT serotypes, BoNT/A and BoNT/B were injected in this model both 
peripherally and centrally, BoNT/A did not affect phase I but partially affected 
phase II. Peripheral administration of BoNT/B on the other hand attenuated the 
licking response during phase I but not II; however, central administration had a 
hyperalgesic effect on the interphase (Luvisetto et al., 2006). 
3.1.2.2. Capsaicin model 
Capsaicin, the main component in chilli peppers, is another irritant widely used 
to generate an additional model of inflammatory pain. After binding to the 
TRPV1 ligand-gated cation channel located on C-fibres (Rang et al., 2007),  it 
excites sensory neurons causing intense pain following the release of 
neuropeptides such as substance P and CGRP. After subcutaneous injection 
into the paw, capsaicin reduces the threshold to a range of stimuli including 
mechanical and heat.  Pre-treatment with BoNT/A was found to either 
significantly reduce or completely eliminate the increased response to 
mechanical or thermal stimuli, when applied 6 days prior to induction of the 
45 
 
model, but was ineffective when applied 24 hrs before induction (Bach-Rojecky 
and Lackovic, 2005). Heat hyperalgesia involves excitation and sensitization of 
C-fibres (Field et al., 1999), while mechanical hyperalgesia seems to be 
facilitated by central sensitization (Gilchrist et al., 1996). Furthermore, a 
recombinant BoNT chimera (LC/E-BoTIM/A) generated by genetically fusing 
LC/E to a BoNT/A enzymically-inactive mutant (BoTIM/A) alleviated capsaicin-
evoked nociceptive behaviour in this model; this effect was long-acting (Wang 
et al., 2011).  SNARE-dependent exocytosis contributes to the transfer of 
TRPV1 to the plasma membrane which BoNT/A treatment inhibits.  This 
blockade of exocytosis by BoNT/A may contribute to the positive effects seen in 
these pre-clinical studies. 
3.1.3.  Neuropathic pain models 
3.1.3.1. Peripheral nerve lesion models 
Investigations on this versatile toxin using rodent models of neuropathic pain 
have likewise yielded beneficial effects  (Marinelli et al., 2010, Luvisetto et al., 
2007, Park et al., 2006, Bach-Rojecky et al., 2005).  Several models of 
peripheral nerve lesion have been developed (Figure 3-1) to generate 
neuropathic pain including; the chronic constriction injury model (CCI), partial 
sciatic nerve ligation model (PSL) and L5/L5 spinal nerve ligation (SNL).  The 
CCI model involves loose ties placed over the sciatic nerve with four chromic 
gut ligatures at the mid-thigh level (Bennett and Xie, 1988).  Partial ligation of 
the ipsilateral nerve at the upper-thigh level, compressing approximately 1/3-1/2 
of the sciatic nerve has been employed to generate a model of causalgia 
(Seltzer et al., 1990).  Another model of causalgia involves tight unilateral 
ligation of the L5 and L6 spinal nerves located distal to the dorsal root ganglia 
(Kim and Chung, 1992).  Recently, it was found that a single dose of 
intraplantar or intrathecal BoNT/A significantly attenuated mechanical allodynia 
in both rats and mice, and thermal hyperalgesia in rats, in a CCI model of 
neuropathic pain (Marinelli et al., 2010).  As soon as 24 hrs following 
application, the positive effects were observed and, encouragingly, these were 
long-lasting with a duration of 81 or 25 days following intraplantar injection of 
the higher dose in mice and rats, and 35 days after intrathecal injection in rats.  
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This neurotoxin was also applied to another mouse CCI model and a single 
dose was capable of attenuating chronic pain symptoms for at least 3 weeks 
(Luvisetto et al., 2007).  BoNT/A was applied to an SNL model and it reduced 
both mechanical and cold allodynia for up to 7 days (Park et al., 2006).  
Administration of BoNT/A to a PSL model significantly attenuated both thermal 
and mechanical hyperalgesia in rats at a low dose of 7U/kg (Bach-Rojecky et 
al., 2005).  
 
Figure 3-1 Animal models of neuropathic pain.   
Schematic of the different approaches used to generate a pre-clinical model of 
neuropathic pain by nerve ligation or transection.  The type of neuropathic pain 
symptoms produced by each model is listed in the boxes under each of the model 
names. Abbreviations; M, mechanical allodynia; H, thermal hyperalgesia; C, cold 
allodynia; A, autotomy.  Image taken from Beggs and Salter, 2006.   
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3.1.4. Environmental factors influencing the development of 
pre-clinical pain models 
Environmental factors play a crucial role in the development of a robust and 
reproducible pre-clinical pain model.  Care must be taken in choosing the most 
suitable parameters that match the experimental hypothesis which you are 
evaluating.  Please refer to the following insightful article for an overview of the 
internal and external factors that influence the development of neuropathic pain 
(Vissers et al., 2003).  A study investigating the choice of age on the 
development of pain in a rat spinal ligation model revealed that younger rats 
display much more robust symptoms of chronic pain compared to older animals 
(Chung et al., 1995).  A variety of differences were observed with Sprague 
Dawley rats obtained from different vendors, Charles River rats were fatter and 
displayed higher adrenocorticotropic hormone output than Harlan rats (Pecoraro 
et al., 2006).  The group who developed the partial nerve injury model of 
neuropathic pain by tight ligation of 1/3-1/2 of the sciatic nerve (Seltzer et al., 
1990), found difficulty in reproducing results even though all the variables were 
the same for each study.  After further investigation they found that rats that 
were fed a soy diet perioperatively displayed significantly reduced chronic pain 
behaviour when compared to those on a soy-free diet (Shir et al., 1998).  These 
are just a few examples to illustrate the importance of internal and external 
factors that may affect the development of a robust, reproducible, chronic pain 
in vivo model for evaluating potential therapeutics.    
3.1.5.  Recombinantly-engineered BoNTs 
The individual structural domains of BoNTs infer unique functions (e.g. acceptor 
binding, translocation and protease activity).  Protein engineering provides an 
opportunity to combine characteristics of different serotypes to create a 
therapeutic with the most desirable features.  BoNT/A, /E and others have been 
successfully recombinantly expressed, purified and characterised (Wang et al., 
2011, Lawrence et al., 2007, Dolly et al., 2011).  Encouragingly, the biological 
activities of these recombinant products were equal or greater than that or their 
corresponding native serotypes.  BoNT/E (Lawrence et al., 2007) acts faster 
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than BoNT/A (Wang et al., 2008) in blocking neurotransmitter release; its LC 
cleaves 17 additional SNAP-25 residues than that of /A (Meng et al., 2009, 
Dolly et al., 2009).  Although rBoNT/E retained full biological activity, its duration 
of action is short lived (Dolly et al., 2011).  Interestingly, site-directed 
mutagenesis of rBoNT/A revealed that the longevity of /A is linked to a di-
leucine motif near the C-terminus of its LC (Dolly et al., 2011, Wang et al., 
2011).  A novel recombinant composite toxin was created by attaching LC/E to 
the N-terminus of a protease inactive mutant of BoNT/A.  This innovative 
therapeutic, LC/E-BoTIM/A, bound to sensory neurons, 
internalised/translocated and cleaved SNAP-25, giving a LCE-truncated product 
(Wang et al., 2011).  Another composite toxin was engineered by joining LC/E 
with BoNT/A, providing a double-active therapeutic.  The following pre-clinical 
study aims to investigate the therapeutic efficacies of rBoNT/A, LC/E-BoTIM/A 
and LC/E-BoNT/A (Figure 3-2), in a rodent spinal nerve ligation model of 
neuropathic pain. 
 
Figure 3-2 Recombinantly engineered BoNTs for evaluation in vivo. 
rBoNT/A (removes nine residues from the C terminus of SNAP-25), LC/E-BoTIM/A (an 
enzymatically-inactive mutant of A, delivers a LC/E protease cleaving 17 more C-
terminal residues from SNAP-25 than BoNT/A) and LC/E-BoNT/A (contains the 
combined protease activity of A and E, cleaving 26 SNAP-25 residues). 
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3.2. Aims and objectives 
• To establish a model of chronic pain in the rat by tight ligation of the L5 
and L6 spinal nerves 
• To investigate the efficacies of BoNT-based therapeutics in this in vivo 
model 
3.3. Materials and Methods 
3.3.1. Materials 
Item Catalogue 
number 
Supplier 
Adson tissue forceps  14226 World Precision 
Instruments 
Agricola Retractor  17005-04 InterFocus Ltd. 
Applying instrument 12028-12 InterFocus Ltd. 
Base assembly for  plantar simulation 37450-278 Ugo Basile 
Bead instrument steriliser 34-0575 Harvard apparatus Ltd. 
Bone cutter 16101-10 InterFocus Ltd. 
Curved rongeur 14 cm 16021-14 InterFocus Ltd. 
Dumont # 5 45o angled forceps 14101 World Precision 
Instruments 
Dumont # 5 curved forceps 500232 World Precision 
Instruments 
Dumont # 7 curved forceps 11297-10 InterFocus Ltd. 
Ear tag applicator 52-4717 Harvard apparatus Ltd. 
Ethicon Perma Hand Silk Suture, Non-
Absorbable 
W593 Pan Veterinary Ltd. 
Ethicon Suture  
Absorbable  
VCP3040H Pan Veterinary Ltd. 
Hot/Cold Plate 35100 Ugo Basile 
Incapacitance Tester IN101R Linton Instrumentation 
Ligation hook 10062-12 InterFocus Ltd. 
Michel suture clips 12040-02 InterFocus Ltd. 
Noyes scissors curved 501236 World Precision 
Instruments 
Plantar Test- Hargreaves 37370 Ugo Basile 
Rotarod 76-0239 Harvard apparatus Ltd. 
Touch Test Sensory Evaluator, Kit of 20 1277 Ugo Basile 
Table 3-2 Materials used in pre-clinical studies. 
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3.3.2.  Pre-clinical methods 
3.3.2.1. Animal husbandry 
Male Sprague Dawley rats (Harlan, UK- for SNL studies 001 and 003; Charles 
River, UK- for SNL study 002), weighing between 200-300g at the start of the 
study, were housed in groups of four.  Subjects were maintained under 
standard laboratory conditions with a 12 hr light/dark cycle (lights on at 08.00h) 
with food and water available ad libitum.  The experimental procedures were 
performed in accordance with the guidelines of the Research Ethics Committee, 
Dublin City University, Dublin, Ireland and were carried out under licences 
granted by the Minister for Health and Children under the Cruelty to Animals 
Act, 1876 as amended by European Communities Regulations 2002 and 2005 
(licence number: 100/3609). 
3.3.2.2. Experimental design 
For all studies, rats were allowed to acclimatise for at least one week before 
baseline testing for heat hyperalgesia, weight bearing, mechanical and cold 
allodynia.  Male Sprague Dawley rats were used for all studies; N = 40 (Harlan, 
UK) - 001,   N = 51 (Charles River, UK) - 002 and N = 36 (Harlan, UK) for the 
final study 003.  Surgery was performed over one week and post-surgery data 
collected for all four tests for two weeks for SNL study 001 and for one week for 
SNL studies 002 and 003.  
3.3.2.3. Drug administration 
Drugs were injected by a colleague (to ensure that the tester remained blinded 
to the study) under brief isoflorane gaseous anaesthesia, induced with 5% 
isoflurane in 0.8% O2 and reduced to 2% isoflurane in 0.8% O2 (less than a min 
exposure).  The chosen treatments (rBoNT/A, LC/E-BoTIM/A, LC/E-BoNT/A or 
vehicle) were diluted into a 0.9% saline solution with 0.5% BSA before storage 
on ice until administered.  All treatments were given as a 20 µl volume by intra 
plantar injection into the subcutaneous space beside the third and fourth 
metatarsal bones of the hindpaw (Figure 3-3); following injection, the needle 
was carefully withdrawn to prevent release of the drug upon removal.  
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Figure 3-3 Intraplantar administration of drugs.   
Treatments or vehicle were delivered by intraplantar injection between the 3rd and 4th 
metatarsal of the ipsilateral hindpaw as a 20 µl dose under brief gaseous anaesthesia 
as described above. 
3.3.2.4. Spinal nerve ligation (SNL) 
Surgery was conducted under gaseous anaesthesia, (3-5% isoflurane for 
induction and 2 % for maintenance in 0.8-1% O2).  The L5 and L6 spinal nerve 
ligation model was performed as outlined by (Kim and Chung, 1992).  Briefly, 
the paraspinal muscles were removed to expose the spinal process and sacrum 
(Figure 3-4 A).  Careful removal of L6 spinal process allows clear visibility of the 
L4 and L5 nerves lying beneath (Figure 3-4 B).  The L6 nerve is located just 
beneath the sacrum.   A 6-0 non-absorbable silk thread was placed around 
each nerve and tightly ligated to damage the axons in the nerve.  Sham 
operated animals were prepared in the same manner expect the spinal nerves 
were not ligated.     
Administration site 
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Figure 3-4 Dorsal image of the bony structures at the lower lumber and sacral 
levels.  
A. lower structural magnification after dissection of the paraspinal muscles. B. higher 
structural magnification after removal of the L6 spinal process on the left side. Figures 
A and B taken from Luo, 2004.   C. A sham-operated animal, showing normal flexing of 
the toes.  D. A SNL rat, displaying normal toe flexing of the contralateral limb, while 
toes of the ipsilateral side are held closely together with accompanied swelling. 
3.3.3. Behaviour parameters 
3.3.3.1. Locomotor dysfunction 
Locomotor dysfunction in rats injected with the selected treatment doses were 
investigated by the rotarod test.  Animals were first acclimatised to both the 
tester and the rotating drums to eliminate stress.  Training involved placing the 
animals onto the rotarod with their heads facing in the direction of the rotation at 
both constant and acceleration speeds of 15 RPM and 5-15 RPM, until the 
animal remained on the drum for the duration of the trial and for a minimum of 
three trials (Figure 3-5).  Only those that fulfilled the test criteria were selected 
for the experiment.   
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Figure 3-5 The rotarod.   
This revolving drum is used to assess locomotor dysfunction in the rat (Method 
described above). 
3.3.3.2. Mechanical allodynia 
Mechanical allodynia was assessed by measuring the paw withdrawal threshold 
in response to a range of innocuous hairs as per a published method (Chaplan 
et al., 1994).  Calibrated hairs (Table 3-2) were applied perpendicularly to the 
mid plantar surface of the ipsilateral and contralateral hindpaws.  A positive 
response was recorded if the animal responded with a sudden removal of the 
paw; this was often accompanied with behaviour such as licking, biting or 
flinching of the paw.  No response to the application of the hair was considered 
negative.  As per the Chaplan method, the 15.10g hair was considered the cut-
off point.  Paw withdrawal threshold was determined using the Dixon up-down 
method (Dixon, 1980).  With this, the 2 g hair is initially applied and depending 
on the response (positive or negative), consecutive hairs are applied in either a 
descending or ascending fashion.    
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3.3.3.3. Cold allodynia 
This was assessed following application of a cold plate (Table 3-2) set to 5OC to 
the plantar surface of rat paws (Figure 3-6).  The initial paw withdrawal 
response latency, the total number of withdrawals and the time spent with the 
paw raised over 180 seconds were recorded for both the ipsilateral and 
contralateral hindpaws.  Three measurements were taken for each paw with a 
three to five min rest between recordings to prevent sensitisation of the paw.  A 
cut-off time of 180 seconds was assigned to prevent tissue damage. 
 
Figure 3-6 Measurement of cold allodynia.   
Control and neuropathic animals are placed on a test apparatus cooled to 5oC.  Control 
animals very rarely respond by lifting the paw; however, neuropathic rats respond by 
lifting the injured paw.  Both the number of lifts and the time spent lifting significantly 
increase when compared to the controls.  This image illustrates a neuropathic animal 
positively responding to cold allodynia. 
3.3.3.4. Heat hyperalgesia 
This parameter was assessed by the Hargreaves method (Hargreaves et al., 
1988).  Animals were allowed to acclimatise to a plastic enclosure (Table 3-2, 
Figure 3-7).  A radiant heat source was then applied to the mid plantar region of 
the ipsilateral and contralateral hindpaws.  Intensity was adjusted to achieve a 
response in normal un-operated animals of 12-14 seconds.    Paw withdrawal 
led to an automatic cut-off of the heat source, a maximum cut-off time of 20 
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seconds was assigned to prevent tissue damage.  A minimum of three readings 
were recorded per paw with a 3 min break between readings to prevent 
sensitisation of the paw. 
 
Figure 3-7 The Hargreave’s test.   
Once animals are habituated to the plastic enclosure, an infrared heat source is placed 
under the ipsilateral and contralateral hindpaws.  The responses recorded reflects heat 
hyperalgesia. 
3.3.3.5. Weight bearing 
Changes in weight distribution between the injured and control hind limbs were 
assessed by an Incapacitance tester (Table 3-2) following a published method 
(Bove et al., 2003).  Briefly, animals were placed facing forward on a sloped 
plexiglass chamber, with each hindpaw positioned over the designated force 
plate (Figure 3-8).  Over a period of 5 seconds the force applied by each hind 
limb was averaged to give a number in grams.  Four readings were collected for 
each paw and averaged to get the mean value.  The percentage weight 
distribution of the ipsilateral paw was determined by the following calculation: 
Percentage weight distribution of the ipsilateral hind limb = [((Weight bearing of 
the mean ipsilateral paw)/ (weight bearing of the mean ipsilateral + contralateral 
hindpaws) x 100]. 
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Figure 3-8 Incapacitance tester.   
This instrument is used to measure weight distribution of the ipsilateral and 
contralateral hindpaws.  Animals are placed on a sloped surface and force transducers 
measure the weight placed on each hind limb in grams.  The average of all readings 
per paw are used to calculate the percentage weight distribution on the injured paw as 
described above.  Image taken from Bove et al., 2003.   
3.3.4. Statistical analysis for pre-clinical studies 
Data was analysed with a repeated measures two way analysis of variance 
(ANOVA) with time and drug treatment as factors, using a software package 
Graphpad Prism.  A Dunnet’s post-hoc test was chosen to determine the 
significance between groups.  Data was considered as significant with P < 0.05 
and all results were expressed as means ± standard error of the mean (± SEM).   
3.4. Results 
3.4.1. No significant difference in animal weights was observed 
between treatment groups. 
Administration of treatments had no significant effect on rats’ body weights 
(Figure 3-9) relative to the SNL vehicle treatment group: (A) (Group, F (3, 34) = 
1.22, P = 0.3166), (B) (Group, F (4, 46) = 1.381, P = 0.2552).  Overall, rats 
gained weight during the duration of the studies: (A) (Time, F (19, 646) = 28.71, 
P < 0.0001), (B) (Time, F (12, 552) = 284.0, P < 0.0001).  Weight loss was 
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observed in the rBoNT/A-treated group (A), which suggests that the dose was 
too high; however, this did not reach significance. 
 
 
Figure 3-9 Changes in body weights following treatment with BoNTs or vehicle in 
SNL studies 001 (A) or 002 (B).   
There was no significant effect found on body weights when compared to the control 
(SNL- vehicle) group.  See text for details of statistical analyses. 
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3.4.2. A dose-range study revealed that a high (unacceptable) dose of 
rBoNT/A (20 U/kg) resulted in a drop in body weight that was 
matched with severe loco-motor dysfunction. 
Administration of BoNT-based therapeutics resulted in a slight plateau/drop in 
weight, lasting ~ one day post-treatment in all BoNT-treated groups apart from 
the rBoNT/A group (20 U/kg), which did not begin to gain weight until ~ 5 days 
post-treatment (3-10 A).  Subsequently, animals began to steadily gain weight 
for the duration of the study.  The changes in body weight could not be 
statistically analysed as the N numbers are too low (N = 1-2, per group) for cost 
reasons. 
Treatment with rBoNT/A (20 U/kg) resulted in severe locomotor deficits (Figure 
3-10 B), lasting from the day of treatment until day 5 (corresponding to the drop 
in weight) where it slowly began to recover.  At day 15, one of the group had 
already completely recovered, while the second animal did not completely 
return to baseline (N = 2).  Loco-motor dysfunction was also observed in the 
rBoNT/A (15 U/kg), N = 2, LC/E-BoNT/A (30 U/kg), N = 1 and the LC/E-
BoTIM/A (30 U/kg), N = 1 groups.  N numbers of these groups would need to be 
increased to fully evaluate if these effects are statistically significant. 
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Figure 3-10 Changes in body weights and loco-motor dysfunction following 
treatment with BoNTs or vehicle.   
A) Body weights B) loco-motor dysfunction in acceleration mode.  All groups apart from 
the rBoNT/A-treated animals gained weight throughout the dose-range study.  The 
following treatments led to locomotor dysfunction: rBoNT/A (20U/kg), LCE/BoNT/A (30 
U/kg) and rBoNT/A (15 U/kg).  N = 1-2 per group.  See section 3.3.3.1 for method 
details. 
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3.4.3. LC/E/BoNT/A attenuated mechanical allodynia at days 7 and 19 
post-treatment 
Ligation of the spinal L5 and L6 nerves induced mechanical allodynia in both 
studies (Figure 3-11), (A), (Group, F (4, 39) = 21.85, P < 0.0001), (Time, F (7, 
273) = 21.64, P < 0.0001), (B), (Group, F (4, 20) = 35.67, P < 0.0001), (Time, F 
(7, 140) = 9.105, P < 0.0001).  Post hoc Dunnet’s test revealed that the 
significance between the SNL vehicle and the BoNT-treated groups lie in the 
LCE/BoNT/A (20 U/kg) at days 19 (A) and 7 post treatment (B).    
*
 
*
 
Figure 3-11 Efficacy of BoNT-based therapeutics at relieving mechanical 
allodynia.   
A) SNL study 002, B) SNL study 003.  LC/E-BoNT/A significantly improved mechanical 
allodynia at days 7 (B) and 19 (A) post treatment.  Refer to text for statistical analyses.  
See section 3.3.3.2 for method details. 
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3.4.4. LC/E-BoTIM/A and LC/E-BoNT/A significantly increased the 
latency of the first paw withdrawal in response to cold allodynia 
at days 15 and 9, respectively 
SNL surgery successfully developed cold allodynia, a desired feature of 
neuropathic pain in all three studies (Figure 3-12) A), B) and C).  The latency of 
the first paw withdrawal decreased significantly in all SNL groups and this 
feature remained significant for the duration of all three studies.  (A), (Group, F 
(3, 30) = 120.9, P < 0.0001, (Time, F (12, 360) = 33.31, P < 0.0001, (B), 
(Group, F (4, 38) = 16.47, P < 0.0001), (Time, F (8, 304) = 24.54, P < 0.0001, 
(C), (Group, F (4, 38) = 85.52, P < 0.0001), (Time, F (11, 418) = 93.02, P < 
0.0001).  A Dunnet’s post hoc between the vehicle and all other groups, 
revealed a significant increase in paw withdrawal latency at day 15 post 
treatment in the LC/E-BoTIM/A (20U/kg) treated group, P ≤ 0.05 (A) and at day 
9 post treatment in the LC/E-BoNT/A group (C).  The SNL vehicle control group 
remained significant when compared to the sham control group for all time-
points post-surgery, indicating that this neuropathic pain feature is long lasting. 
*
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Figure 3-12 Changes in cold allodynia paw withdrawal latencies, following 
administration of drug treatments.   
Ligation of spinal nerves significantly reduced paw withdrawal latencies to cold stimuli.  
Treatment with either LC/E-BoTIM/A (A) or LC/E-BoNT/A (C) significantly attenuated 
this allodynia at days 15 and 9, respectively.  Refer to text for statistical analyses. A) 
SNL study 001, B) SNL study 002 and C) SNL study 003.  See section 3.3.3.3 for 
method details. 
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3.4.5. SNL surgery significantly increased the total paw withdrawal 
latency to cold allodynia; no significant increase in latencies was 
found between the SNL vehicle and BoNT-treated groups 
Following SNL surgery, the total paw withdrawal latencies significantly 
increased within groups (Group, F (4, 37) = 7.244, P = 0.0002), this significance 
lasted from day 7 post-surgery until the end of the study (Time, F (8, 296) = 
18.64, P < 0.0001).  Post hoc Dunnet’s test revealed that when the vehicle SNL 
group was compared to all other groups at any given time point; no significance 
was found between the SNL vehicle and SNL BoNT-treated groups, 
significance was found only between the sham and SNL vehicle groups (Figure 
3-13). 
 
Figure 3-13 Total ipsilateral paw withdrawal latency to cold allodynia.   
The total time spent lifting, significantly increased post-surgery.  However, no effect 
was observed in the drug treated groups.  Refer to text for details of statistical 
analyses.  See section 3.3.3.3 for method details. 
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3.4.6. Treatment with BoNTs revealed a significant decrease in the 
cumulative number of ipsilateral cold paw withdrawal lifts post-
treatment when compared to the SNL vehicle treated group at 
days 7, 13 and 15 for LC/E-BoTIM/A and at day 15 for rBoNT/A 
SNL surgery produced a model of chronic pain with statistical significance in the 
total number of ipsilateral hind  paw lifts between groups and over time (Figure 
3-14), A) (Group, F (3, 30) = 18.26, P < 0.0001), (Time, F (12, 360) = 21.96, P < 
0.0001), B) (Group, F (4, 38) = 9.271, P < 0.0001), (Time, F (11, 418) = 12.79, 
P < 0.0001).  C), (Group, F (4, 39) = 16.19, P < 0.0001), (Time, F (11, 429) = 
32.45, P < 0.0001).  Dunnet’s post hoc analysis revealed, A) a statistical effect 
between the SNL vehicle group and the LCE-BoTIM/A group at days 7, 13 and 
15 post treatment and at day 15 in the rBoNT/A treatment group.  For B) and 
C), Post hoc analysis revealed that significance lies between the SNL and sham 
operated groups. 
**
*
**
***
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Figure 3-14 Cumulative number of ipsilateral paw withdrawal lifts.   
A) SNL study 001, B) SNL study 002, C) SNL study 003.  SNL surgery significantly 
increased the total number of paw withdrawals in response to cold allodynia in all SNL 
groups compared to the sham un-operated group.  Treatment with BoNTs decreased 
the cumulative paw withdrawals to this cold stimuli in both the LC/E-BoTIM/A and 
LC/E-BoNT/A groups at (7, 13 and 15) and (15) days post treatment A).  No 
significance was found between the BoNT and SNL vehicle treated groups B) and C).  
Please refer to text for statistical analyses.  See section 3.3.3.3 for method details. 
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3.4.7. BoNTs significantly attenuated heat hyperalgesia in the LC/E-
BoTIM/A group at day 10 and in the LC/E-BoNT/A group at days 
19 and 25 post treatment 
Analysis of the Hargreaves data from SNL studies 001, 002 and 003 
revealed that SNL surgery successfully induced heat hyperalgesia which 
was significant when compared to the sham control group and this effect 
lasted through time (Figure 3-15), A) (Group, F (3, 31) = 9.540 P = 0.0001), 
(Time, F (6, 186) = 27.63 P < 0.0001), B) (Group, F (4, 42) = 6.716, P = 
0.0003), (Time, F (6, 252) = 13.27, P < 0.0001), C) (Group, F (4, 39) = 
25.43, P < 0.0001), (Time, F (9, 351) = 22.28, P < 0.0001). 
However, closer examination with a Dunnet’s Post-hoc test, comparing the 
SNL vehicle group to all other groups, revealed significance only between 
the SNL vehicle and sham groups, A), P ≤ 0.01, B), P ≤ 0.001, C), P ≤ 
0.0001.  In A) this significance lasted from days -14 until day 0, no 
significance was found between treated groups and the SNL vehicle group 
at days 5, 11 and 17 post-treatment.  In B) this significance was found only 
at days 0 and 7, no significant difference was found between the SNL 
vehicle and other groups at any other time-points.  In C) this significance 
was the most robust and lasted from days 0 to 25.  When the SNL vehicle 
group was compared to the BoNT-treated groups, a significant increase in 
paw withdrawal latency to heat hyperalgesia was found in the LC/E-BoTIM/A 
(20 U/kg) group at day 10 post treatment, P ≤ 0.05, and at days 19 and 25 in 
the rBoNT/A group (10 U/kg), P ≤ 0.05. 
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* * *
 
Figure 3-15 Efficacy of BoNTs on heat hyperalgesia. 
A) SNL study 001, B) 002 and C) 003.  Spinal nerve ligation significantly reduced paw 
withdrawal latencies when compared to the sham group.  However, no significant effect 
was found between the SNL vehicle and BoNT-treated groups in A) or B).  In C) 
treatment with LC/E-BoTIM/A or LC/E-BoNT/A significantly improved paw withdrawal 
latencies to heat hyperalgesia at day 10 and days 19 and 25, respectively.  See text for 
statistical analyses.  See section 3.3.3.4 for method details. 
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3.4.8. SNL surgery significantly decreased the weight placed on 
ipsilateral hindpaws post-operatively  
Ligation of L5 and L6 spinal nerves, significantly decreased the weight placed 
on the ipsilateral-lateral hindpaws (Figure 3-16) A), (Group, F (3, 34) = 31.60, P 
< 0.0001), (Time, F (9, 306) = 23.72, P < 0.0001).  B), (Group, F (4, 46) = 
13.60, P < 0.0001), (Time, F (6, 276) = 13.75, P < 0.0001).  C), (Group, F (4, 
39) = 26.38, P < 0.0001), (Time, F (8, 312) = 58.66, P < 0.0001.  A), 
significance was found between the sham and the SNL vehicle group at all 
time-points post-surgery until day 17; there was no significance found between 
the SNL vehicle and sham groups at day 23.  In B), Significance was only found 
between the SNL vehicle group and the sham group from days -7 to 13; no 
significance was found between these groups at days 19 and 23 post treatment.  
In C) weight bearing in all SNL groups remained statistically significant to the 
sham control group for the duration of the study. 
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Figure 3-16 Changes in ipsilateral weight bearing following sham or SNL surgery.   
SNL surgery significantly decreased weight placed on the ipsilateral hindpaws in all 
three studies.  No significant effect in weight bearing was observed between 
treatments.  See section 3.3.3.5 for method details. 
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3.5. Discussion and conclusions 
A pre-clinical rat model of chronic neuropathic pain involving tight ligation of the 
L5 and L6 spinal nerves was established in-house to examine the efficacies of 
BoNT-based anti-nociceptives.  No significant difference in animal weights was 
found between treatment groups, however, in the first study, a drop in body 
weight that did not reach significance was observed in the rBoNT/A (20 U/kg).  
It was suspected that this dose was too high and was causing loco-motor 
deficits.  A rota-rod was purchased to evaluate this hypothesis, treatment with 
rBoNT/A (20 U/kg) did indeed produce severe loco-motor dysfunction lasting 
from days 2-5 and gradually improving to ~ day 18 where the recovery reached 
a plateau.  This pattern of recovery could reflect the duration of action of the 
toxin.  Although no difference between body weights was observed between 
treatment groups, there were clear differences observed between suppliers.  
For the first and third study, animals were purchased from Harlan, UK, whereas 
for the second study the vendor was changed to Charles Rivers UK because 
there was a promotion at the time.  Charles River rats grew much more rapidly 
than Harlan animals; while rats supplied from the latter vendor appeared 
calmer, were easier to train and habituated quicker to tests.  LC/E-BoNT/A 
significantly attenuated mechanical allodynia at days 7 and 19 post-treatment 
when compared to the vehicle control group.  LC/E-BoTIM/A and LC/E-BoNT/A 
significantly increased the latency of first paw withdrawal in response to cold 
allodynia at days 15 and 9, respectively.  The cumulative number of ipsilateral 
lifts also significantly decreased at days 7, 13 and 15 for LC/E-BoTIM/A and at 
day 15 for rBoNT/A.  LC/E-BoTIM/A and LC/E-BoNT/A attenuated heat 
hyperalgesia at days 10 (LC/E-BoTIM/A) and 19 and 25 (LC/E-BoNT/A).  
Treatment with BoNTs appeared most efficacious at relieving mechanical and 
cold allodynia.  Heat hyperalgesia and weight bearing appear less responsive to 
treatment.  Together these preliminary findings support the use of BoNTs in 
treating chronic pain conditions. 
For the third study, rats were fed a soybean-free diet, as evidence suggests that 
partial nerve ligation animals on a soy diet perioperatively displayed significantly 
reduced chronic pain behaviour when compared to those on a soy-free diet 
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(Shir et al., 1998).  For the final study, L5 and L6 nerves were double ligated to 
prevent natural recovery in the model.  Encouragingly, this third study revealed 
the most robust neuropathic pain features when compared to the other two 
studies.  
3.6. Future work 
These in vivo results provide some evidence for the ability of BoNT to relieve 
pain.  Behavioural parameters most affected by treatment with BoNTs 
(mechanical and cold allodynia) were dissected out, along with the most 
accurate readouts for each test.  These preliminary investigations lay the 
foundation for more sophisticated experiments.  Currently, a colleague is using 
the spared nerve injury model of neuropathic pain, has obtained exciting data 
with 15 U/kg of rBoNT/A and 75 U/kg of LC/E-BoNT/A. This established robust 
model could be used to screen novel targeted BoNTs in the future.   
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4. DEVELOPMENT OF ANTIBODIES TO A PRIME PAIN 
TARGET 
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4.1. Background 
4.1.1. Antibodies 
Antibodies (immunoglobulins) are proteins that are recruited by the immune 
system to fight again infections.  They are highly specific and recognise unique 
antigens that are located within foreign organisms.  They are categorised into 
five classes (IgG, IgM, IgA, IgD, IgE) depending on their structure.  IgG and IgM 
have two and ten binding sites, respectively; this enhances their avidity.  IgG is 
a Y shaped antibody, containing two antigen binding Fab heavy chains (50 K) 
and two light chains (25 K) Fc domains joined together by disulphide bonds.  
Single chain variable fragment scFv antibodies (~ 30 K) are composed of the 
VH and VL domains joined together by a flexible polypeptide linker.  Their 
smaller size allows better target penetration.  Antibodies may be used as 
innovative tools to target potential anti-nociceptives.  
4.1.2. Structure of transient receptor potential vanilliod 1 (TRPV1) 
The TRPV1 polymodal receptor was first cloned in 1997 (Caterina et al., 1997); 
it is a membrane protein cation channel of 838 amino acids and may be 
activated by a variety of stimuli including: capsaicin, heat (> 43oC), low pH (5.2) 
and various lipids.  It has a tetrameric structure with six transmembrane 
domains, a pore/gate hydrophobic region located between the fifth and sixth 
domains and C- and N- termini positioned internally (Figure 4-1).  TRPV1 has 
structural similarity to the voltage gated K+ channel.  Activation and opening of 
TRP channels depolarises excitable cells and regulates Ca2+ and K+ channels.   
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Figure 4-1 Structure of TRPV1.   
TRPV1 has six transmembrane spanning domains and a pore/gate forming region 
located between the fifth and sixth subunits.  It is activated by a range of activators 
including; capsaicin, heat and protons.  Ankyrin repeats (AnkR) are present in TRPV 
channels and are believed to facilitate anchoring.  The TRP box is an amino acid 
sequence that is involved in gating of the channel, opening of the channel/gate allows 
entry of Na2+ and Ca2+.  Abbreviations; aa, amino acids, AnkR, ankyrin repeats, PDZ, 
postsynaptic density protein 95.  Image taken from Moran et al., 2011.     
4.1.3. TRPV1 as a prime pain target 
TRPV1 is located in the peripheral and central nervous systems, being 
expressed in sensory ganglia and C and Aδ fibres.  Following injury or 
inflammation, pain mediators are released that activate TRPV1 receptors 
(Figure 4-2).  TRPV1 is co-expressed along with TRPA1 in the peripheral 
nociceptor (Figure 4-3 A).  Following activation, action potentials are generated 
and propagated to the central nervous system stimulating the release of 
neurotransmitters.  Substances released at the peripheral nociceptor can initiate 
signal transduction pathways that contribute to the trafficking of TRPV1 (Figure 
4-3 B). 
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Figure 4-2 Expression and activation of TRPV1.  
TRPV1 is primarily expressed in sensory afferents of the peripheral nervous system 
and may be activated by a variety of mediators such as heat and protons (a).  TRPV1 
is expressed along with Trk A, bradykinin, purine and other receptors.  In response to 
activation, sensory neurons release pain mediators such as CGRP and substance P.  
In turn, signals propagated to the CNS are amplified and painful sensations are 
perceived by the brain. Abbreviations: 5HTR, serotonin receptor; BK, bradykinin; EP, 
prostaglandin E2 receptor; ET, endothelin receptor; H1, histamine receptor 1; HIS, 
histamine; IL1R, interleukin 1 receptor; PGE2, prostaglandin E2; SP, substance P. 
Image taken from Szallasi et al., 2006.      
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Figure 4-3 Expression of TRP channels in nociceptors (A) and changes produced 
by inflammation (B).   
TRPV1 is co-expressed along with TRPA1 in peripheral nociceptors (A).  Painful stimuli 
directly activate these pain receptors in the peripheral nervous system, converting 
these stimuli into electrical impulses and conveying these impulses to the central 
A 
B 
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nervous system; this is accompanied by the release of peptides/inflammatory 
mediators producing neurogenic inflammation and activation of signal transduction 
pathways.  (B) These pathways may phosphorylate TRPV1 and other TRP channels 
and affect their trafficking to the plasma membrane.  Growth factors released in 
response to pain, increase the expression of TRPV1 in the peripheral terminals.  
Together these changes create an altered processing environment lowering the 
activation threshold of nociceptors.  Abbreviations; CGRP, calcitonin gene-related 
peptide; B2, bradykinin receptor B2; ERK, extracellular signal-regulated kinase; ETAR, 
endothelin receptor type A; GDNF, glial-cell-derived neurotrophic factor; NK1, 
neurokinin receptor 1; PAR2, protease-activated receptor 2; PGE2, prostaglandin E2; 
PI3K, phosphoinositide 3-kinase; PK, protein kinase; PKR, prokineticin receptor; TNFα, 
tumour necrosis factor α; TNFR1, TNF receptor 1; TRKA, tyrosine kinase receptor A. 
Images taken from Patapoutian et al., 2009.     
4.1.4. Intracellular trafficking of TRPV1 
Regulated exocytosis is believed to be responsible for TRPV1 receptor surface 
translocation during nociceptor sensitisation.  A yeast two hybrid system was 
used to identify proteins that interact with the N terminus of TRPV1.  This 
platform identified two proteins-Snapin and Synaptotagmin IX that interact both 
in vitro and in vivo with TRPV1.  Both of these proteins block protein kinase C 
(PKC) signalling of TRPV1 while PKC activation leads to fast TRPV1 trafficking 
to the plasma membrane; the latter is inhibited by BoNT/A.  This study 
concluded that PKC signalling contributes to SNARE-dependent exocytosis of 
TRPV1 to the plasma membrane (Morenilla-Palao et al., 2004). 
To further investigate this hypothesis, an additional inhibitor of exocytosis was 
used to evaluate SNARE regulated exocytosis of TRPV1.  It was found that 
TRPV1 induced sensitisation stimulated by NGF, ATP and IGF-1; this was 
accompanied by increased plasma membrane expression that was successfully 
blocked by application of a 6-mer peptide.  On the other hand, TRPV1 
sensitisation induced by IL-1β, bradykinin and artemin were not blocked.  This 
data concluded that TRPV1 is involved in the mechanism by which some 
proinflammatory agents sensitise nociceptors while other proinflammatory 
agents act independently of TRPV1 (Camprubi-Robles et al., 2009).  
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The mechanisms involved in TRPV1 desensitisation were evaluated in a recent 
study whereby both sensory neurons and HEK transfected TRPV1 cells were 
exposed to capsaicin-an agonist of TRPV1.  This induced TRPV1 receptor 
endocytosis followed by lysosomal degradation in both systems.  TRPV1 
internalisation as a result of agonist stimulation and Ca2+ flux was mediated by 
a clathrin and dynamin independent endocytic pathway controlled by PKA-
dependent phosphorylation.  These findings concluded that long term exposure 
to agonists of TRPV1 led to receptor down regulation by endocytosis followed 
by lysosomal degradation (Sanz-Salvador et al., 2012).  
Experiments in this chapter, were conducted to determine if the α-TRPV1 
antibodies generated are internalised and trafficked in a similar fashion to that 
of TRPV1.  Capsaisin was applied to stimulate uptake of the antibody and 
bafilomycin A1 to increase visibility of vesicular structures (Figure 4-4). 
 
Figure 4-4 Schematic to illustrate the hypothesised intracellular trafficking of 
TRPV1 in HEK cells.  
Capsaicin is an agonist of TRPV1 which activates the TRPV1 channel and stimulates 
TRPV1 internalisation.  Bafilomycin A1 is a specific inhibitor of vacuolar-type H(+)-
ATPase and blocks acidification; this should lead to accumulation of the antibody and 
increased visibility of vesicular staining by preventing the passage of TRPV1 through 
acidified compartments.  Abbreviations; H+, protons. 
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4.1.5. Alterations in the expression of TRPV1 following treatment with 
BoNT 
The expression of TRPV1 on the plasma membrane is regulated by exocytosis 
and increased levels are present in painful states (Camprubi-Robles et al., 
2009, Akbar et al., 2008, Gopinath et al., 2005).  Application of BoNT/A, a 
potent inhibitor of exocytosis, is believed to disrupt TRPV1 trafficking to the 
plasma membrane and, in turn; attenuate pain.  A number of studies support 
this theory; reduced TRPV1 was found in human bladder samples from patients 
that had BoNT/A locally administered (Apostolidis et al., 2005).  A recent study 
(Shimizu et al., 2012) where BoNT/A was injected into rat trigeminal ganglion 
neurons revealed reduced TRPV1 immunoreactivity in both the trigeminal 
ganglion and the fibre terminals.  Cleavage of its substrate SNAP-25, was 
observed two days post-treatment and remained for a minimum of two weeks.  
A surface biotinylation assay confirmed that BoNT/A blocked TRPV1 trafficking 
to the plasma membrane.  It was concluded from this study that BoNT/A 
reduces TRPV1 expression by inhibiting its trafficking to the plasma membrane 
and proteasome degradation (Figure 4-5).  A ventral root transection rodent 
pain model was used to investigate the actions of BoNT/A on pain thresholds 
and TRPV1 expression in the DRG.  Immunohistochemistry and Western 
blotting data revealed that treatment with BoNT/A significantly decreased 
TRPV1 expression which was accompanied with a partial attenuation of pain 
thresholds (Xiao et al., 2013).   
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Figure 4-5 Changes in TRPV1 expression following treatment with BoNT/A 
The expression of TRPV1 on the plasma membrane is regulated by exocytosis.  Fusion 
of TRPV1 containing vesicles (1) with the plasma membrane under desired conditions 
leads to exocytosis (2) and expression of TRPV1 on the plasma membrane (3).  
Application of BoNT/A, binds to its acceptor SV2C, cleaves its substrate SNAP-25 and 
disrupts exocytosis.  This prevents the translocation of TRPV1 to the plasma 
membrane, inducing ubiquitination (Ub) and proteasomal degradation of (1’) leading to 
reduction of TRPV1 expression (2’).  Image taken from Shimizu et al., 2012.    
4.2. Aims and objectives: 
 To develop and characterise antibodies to human TRPV1. 
 To investigate the internalisation and trafficking of α-TRPV1 antibodies. 
4.3. Results 
4.3.1. Target selection-peptides chosen and rationale 
Two epitopes were selected, corresponding to different regions of the human 
TRPV1 protein sequence (Figure 4-6).  The first corresponds to amino acids 
606-621 and shares 69% identity to rat, and 63% identity to mouse.  This 
peptide is referred to as TRPV1-A.  The second epitope (TRPV1-B) 
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corresponds to amino acids 637-649 and shares 100% identity to rat and was, 
therefore, expected to bind both rat and human TRPV1. 
   
Figure 4-6 Epitopes selected from the human TRPV1 protein sequence for 
antibody generation.   
hTRPV1-A and hTRPV1-B external epitopes were selected, corresponding to the 
following amino acids: H-S-L-P-S-E-S-T-S-H-R-W-R-G-P-A-C-OH (amino acids 606-
621 of the hTRPV1 sequence for –A (blue square)) and ELFKFTIGMGDLE-Cys 
(amino acids 637-649 of the hTRPV1 sequence for –B (red square)). Abbreviations 
include; PIP2, phosphatidylinositol (4,5)-bisphosphate; CaM, calmodulin; CaMKII, 
calmodulin kinase II; PKA, protein kinase A; PKC, protein kinase C; S, serine; T, 
threonine.  Image modified from Tominaga and Tominaga, 2005.    
4.3.2. A commercial α-TRPV1 antibody to the same epitope but in rat 
successfully stained TRPV1 in sensory neurons of rat dorsal root 
ganglia 
Review of the literature revealed that an antibody to a similar region to that of 
the TRPV1-A peptide was available commercially but had been generated to rat 
TRPV1.  Sensory dorsal root ganglia neurons P5 were cultured and stained; 
specific staining of TRPV1 was achieved with this commercial antibody (Figure 
4-7). 
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Figure 4-7 Staining of sensory dorsal root ganglia neurons with the commercial 
α-rTRPV1 antibody. 
A- Brightfield image for B.  B- No staining was observed with the goat-α-rabbit-Alexa 
568 secondary only control antibody (1:1500 dilution).  C- Brightfield image for D.  D- 
Positive α- rTRPV1 staining was observed after overnight incubation with the 
commercial rTRPV1 extracellular antibody 1:50 dilution (Alomone); 2o antibody- goat-α-
rabbit-Alexa 568 1:1500 dilution.  X 10 magnification, bar represents 100 µm.  
Arrowheads represent cell bodies.  Staining of intact sensory neurons was carried out 
as described in section 2.4.1.2 of the Materials and Methods chapter. 
4.3.3. Serum from a rabbit immunised with TRPV1-A and TRPV1-B 
peptides revealed pronounced immunogenicity towards the α-
TRPV1-A peptide 
The rabbit (named DAKA for identification purposes) immunised with a 
combination of TRPV1-A and TRPV1-B produced pronounced immunogenicity 
towards the α-TRPV1-A peptide with a direct ELISA titre of ~ 1/100000 against 
α-TRPV1-A-KLH coated plates (Figure 4-8).  However, the resultant polyclonal 
antibodies were unreactive to rat TRPV1 (Figure 4.9), suggestive of an issue 
with the TRPV1-B peptide synthesis.  Closer examination of the TRPV1-B-BSA 
peptide, confirmed this, as no protein of 66 K was visualised after separation on 
SDS-PAGE (not shown). 
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Figure 4-8 Direct ELISA from DAKA. 
Nunc plates were coated overnight with 2 µg/mL of TRPV1-A-KLH. Plates were 
blocked with 200 µl of 5% milk marvel for 1 hr in PBS.  Serial dilutions of the serum 
were prepared in PBST with 5 % milk marvel; 100 µl of each serial dilution was added 
for 1 hr at room temperature.  Plates were then washed 3 times in both PBST and 
PBS.   Donkey-α-rabbit HRP secondary antibody (1:1000) was added to each well in 
PBST with 5% BSA and incubated for 1 hr at room temperature.  This was followed by 
3 washes with PBST and PBS.  TMB (100 µl) was added to each well and the reaction 
monitored.  The reaction was stopped with 1M HCL (50 µl) and the plate read on a 
Tecan plate reader.  PB- prebleed, FB- final bleed.  Absorbance values were read at 
450 nm.  Direct ELISA was carried out as described in section 2.2.2.3 of the Materials 
and Methods chapter. 
4.3.4. α-hTRPV1-A polyclonal antibodies from the DAKA crude serum 
detected human but not rat TRPV1  
HEK cells were transiently transfected with pcDNA3 encoding either human or 
rat TRPV1 or left untreated for 24 or 48 hrs prior to lysis in SDS sample buffer.  
Each sample (10 µl) was separated by SDS-PAGE and subjected to Western 
blotting.  Membranes were sequentially probed with the following antibodies, i) 
Serum from DAKA immunised with α-hTRPV1-A (external loop) ii) Commercial 
α-rTRPV1 (external loop Alomone).  α-TRPV1-A polyclonal serum detected 
human but not rat TRPV1 (Figure 4-9 A). Commercial α-rTRPV1 antibodies 
detected rat but not human TRPV1 (Figure 4-9 B).  When the membrane of A 
was washed with NaN3 and incubated with commercial α-rTRPV1 antibodies, it 
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detected rTRPV1 (Figure 4-9 C).  When the membrane of B was incubated with 
the polyclonal α-hTRPV1-A antibodies, it also detected hTRPV1 (Figure 4-9 D).  
In conclusion, Western blot analysis revealed that the polyclonal serum from 
DAKA detected human but not rat TRPV1 (Figure 4-9).  HEK-WT untransfected 
cells were used as an experimental control, TRPV1 was not detected in this 
lane, however, a protein band of a higher molecular weight was detected in this 
lane and in all other HEK cell lanes, this band appears to be specific to a protein 
in HEK cells. 
  
Figure 4-9 Detection of either human or rat TRPV1 by Western blotting of 
transiently-transfected HEK cell lysates probed with polyclonal TRPV1-A DAKA 
serum or commercial α-rat TRPV1 external antibody.   
HEK cells were transiently transfected with pcDNA3 encoding human (lanes 1, 4) or rat 
(lanes 2, 5) TRPV1 or left untransfected (lanes 3, 6) for 24 (lanes 1, 2, 3) or 48 hrs 
(lanes 4, 5, 6).  Samples were subsequently lysed and separated by SDS-PAGE and 
Western blotted.  A. The membrane was probed with α-hTRPV1-A polyclonal serum 
and detected human TRPV1, no signal was detected for rat TRPV1 or for the non-
transfected control cells.  B. The commercial α-rTRPV1 antibody detected rat but not 
human TRPV1, again no signal was detected in the negative control lane.  C. When the 
membrane of A was washed with NaN3 and developed with the commercial α-rTRPV1 
antibody, it detected rat TRPV1.  D.  The membrane of B was incubated with the α-
hTRPV1-A polyclonal serum and subsequently detected human TRPV1, some signal 
from the previous incubation remained as it was not washed out.  Further method 
details can be found in section 2.2.2.11 of the Materials and Methods chapter. 
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4.3.5. α-hTRPV1-A antibodies were purified by protein A-Sepharose 
Polyclonal antibodies from the hTRPV1-A immunized DAKA rabbit serum were 
purified by protein A-Sepharose.  Protein stained gel revealed the anticipated 
antibody heavy and light chains of ~ 50 and 25 K, respectively (Figure 4-10). 
 
Figure 4-10 Purification of α-hTRPV1 polyclonal antibodies. 
IgGs from α-hTRPV1 polyclonal serum were purified by protein A-sepharose and 
characterised by Coomassie stained 12 % gel.  In the presence of reducing agent DTT, 
proteins separated into their expected heavy and light chains of 50 and 25 K, 
respectively.  Method details can be found in section 2.2.2.9.2. 
4.3.6. α-hTRPV1-A purified IgGs bind specifically to  hTRPV1 in a dose-
dependent manner and are internalised by hTRPV1 transiently-
transfected HEK cells 
Key immunocytochemistry experiments were performed to determine if α-
hTRPV1-A antibodies bind to and are internalized by hTRPV1-expressing cells.  
To evaluate this, HEK cells transiently over-expressing hTRPV1 were stained 
with purified polyclonal α-hTRPV1 antibodies.  Encouragingly, TRPV1-positive 
staining was observed in both permeabilised and non-permeabilised conditions, 
indicative of hTRPV1 antibodies binding to TRPV1; the specificity of this binding 
was further confirmed by an absence of staining in untransfected HEK-WT cells 
(Figure 4-11).   Immunocytochemistry (Figure 4-12) and Western blotting 
(Figure 4-13) of transiently-transfected hTRPV1 HEK cells, with increasing 
concentrations α-hTRPV1-A antibodies revealed that antibody binding is dose-
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dependent and specific to TRPV1 (as it was completely blocked by addition of a 
100 fold molar excess of the hTRPV1-A blocking peptide).   
 
Figure 4-11 α-hTRPV1 antibody staining of permeabilised, unpermeabilised and 
live HEK cells transiently transfected with pcDNA3 encoding hTRPV1.   
HEK cells were transiently transfected with pcDNA3 encoding either hTRPV1 or left 
untreated for 24 hrs.  α–hTRPV1-IgGs were applied to either permeabilised (A, B), 
unpermeabilised (C, D) or to live cells (E).  Positive staining specific to hTRPV1 was 
achieved and lack of signal in the HEK-WT cells (B, D and F).  HEK-TRPV1 live cell 
staining was predominately located around the plasma membrane (E). Further details 
regarding methods can be found in sections 2.4.1.1, 2.4.1.2 and 2.4.1.3 of the 
Materials and Methods chapter. 
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Figure 4-12 α-hTRPV1-IgGs dose-dependently-detect hTRPV1.   
HEK cells were transiently transfected with pcDNA3 encoding either human or rat 
TRPV1 or left untreated for 24 hrs.  Subsequently, cells were blocked, fixed and 
incubated overnight with increasing concentrations of α-hTRPV1 antibodies with or 
without a 100-fold molar excess of the free TRPV1-A peptide.  Panels A-H- HEK cells 
transiently transfected with hTRPV1 were subsequently incubated with increasing 
concentrations of α-TRPV1 IgGs (µg/mL)- A and E- 0.1, B and F- 0.3, C and G- 1 and 
D and H- 3 µg/mL.  Panels A-D were incubated without inclusion of the blocking 
TRPV1-A free peptide – (BP), while panels E-H were incubated with addition of a 100-
fold molar excess of the free TRPV1-A peptide.  Panel I – HEK hTRPV1 transfected 
cells incubated only with the Alexa-conjugated goat anti-rabbit IgG secondary antibody 
(1:500).  Method details can be found in section 2.4.1.2. 
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Figure 4-13 Western blot of the reactivities of increasing concentrations of 
purified α-hTRPV1 antibodies with hTRPV1 HEK cell lysates, in the presence or 
absence of blocking peptide.  
HEK cells were transiently transfected with human or rat TRPV1 or left untreated for 24 
hrs prior to lysis in SDS sample buffer.  Each sample (10 µl) was separated by SDS-
PAGE and Western blotted.  Membranes were incubated with the α-hTRPV1-IgG in 
increasing concentrations, with or without the control free TRPV1-A blocking peptide 
(100-fold molar excess); the control peptide successfully blocked α-hTRPV1-A-
antibody binding sites, thus, no TRPV1 was detected (~ 95 K).   TRPV1 was also 
absent in the 2O antibody only control treated hTRPV1 transfected HEK cells (donkey α 
rabbit HRP IgG).  TRPV1 was only present in hTRPV1 transfected cells and absent 
from rTRPV1 or WT cells.  Method details can be found in section 2.2.2.11 of the 
Materials and Methods chapter. 
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4.3.7. α-hTRPV1-A antibody binds to HEK-hTRPV1 transfected cells 
Staining of HEK cells transfected with or without hTRPV1 revealed that antibody 
binding increases with time.  This staining is specific to hTRPV1 as no definite 
staining was observed in non-transfected control cells (Figure 4-14).   
 
Figure 4-14 Time required for binding of hTRPV1-A antibodies to HEK-TRPV1 
transfected cells.  
IgG- red, DAPI- blue. α-hTRPV1-A antibodies (10 µg/mL) did not bind to HEK-WT 
control cells.  hTRPV1-A antibodies bound to HEK-TRPV1 transiently-transfected cells. 
Scale bar represents 100 µm, objective- X 60.  Further details can be found in section 
2.4.1.3 of the Materials and Methods chapter. 
4.3.8. Live cell staining with washout after antibody binding illustrates 
vesicular staining 
Antibody staining of live cells with washout illustrates the transition of the 
antibody over time.  Treatment with bafilomycin A1 (a specific inhibitor of 
vacuolar-type H(+)-ATPase) lead to an accumulation and increased visibility of 
vesicular antibody staining, suggestive that the antibody undergoes trafficking 
through acidified vesicles (Figure 4-15).  Co-staining with suitable markers e.g. 
a lysosomal-associated membrane protein antibody would be required to 
confirm the route of this transition.  
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Figure 4-15 hTRPV1-A IgG cell staining with or without washout or bafilomycin 
A1.  
Cells were incubated with 10 µg/mL of hTRPV1-A antibodies, with or without 
bafilomycin A1 (100 nM) for 60 mins.  This was followed by either washout or no 
washout and incubation for an additional 90 mins.  Additional method details can be 
found in section 2.4.1.4. 
4.3.9. Pre-treatment with filipin blocked endocytosis of the antibody 
indicating that it utilises lipid rafts 
Pre-treatment with 6 µg of filipin per well (an inhibitor of lipid rafts), followed by 
antibody incubation overnight resulted in intense plasma membrane staining 
without labelling of vesicles; endocytosis of the antibody was prevented by 
filipin, suggesting that TRPV1-A utilises lipid rafts (Figure 4-16).   
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Figure 4-16 Pre-treatment with filipin followed by α-hTRPV1 antibody binding.  
HEK-TRPV1 transfected cells were pre-treated with 6 µg filipin/well followed by 10 
µg/mL IgG/well.  Objective X 60, Bar 100 µm, Exposure red- 500 ms, blue- 200 ms.  
Further details can be found in section 2.4.1.4 of the Materials and Methods section. 
4.3.10. Capsaisin stimulated antibody uptake and yielded more 
‘vesicular like’ staining 
HEK-TRPV1 transfected cells were incubated with hTRPV1-A antibodies (10 
µg/mL) for 90 mins with 1 µM of capsaicin.  Cells were then washed and 
incubated for an additional 6 hrs.  Vesicular α-hTRPV1-A staining was observed 
in transfected HEK-TRPV1 cells (Figure 4-17), however, No staining was 
observed in the untransfected HEK-WT cells (not shown).  
 
Figure 4-17 Capsaisin stimulated antibody uptake. 
Antibody binding (90 mins), followed by washout and a 6 hr follow up period;  10 µg/mL 
IgG/well, 1 µM capsiacin, HEK-TRPV1 cells.  Objective X 60, Bar 100 µm, Exposure 
red- 500 ms, blue- 200 ms.  Further details can be found in section 2.4.1.3 of the 
Materials and Methods chapter. 
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4.3.11.  An in vitro HEK cell culture model expressing SNAP-25 pIRES 
GFP was established 
HEK cells were transiently transfected with pcDNA3 encoding pIRES GFP or 
left untreated for 48 or 72 hrs.  GFP reactive cells were observed at 48 and 72 
hours; reactivity decreased with incubation time; this could be explained by 
SNAP-25 turnover in the cell or alternatively, SNAP-25 GFP signal could be 
degraded due to cell division (Figures 3-18). 
 
Figure 4-18 SNAP-25-WT pIRES GFP expression.   
HEK cells were transiently transfected with pcDNA3 encoding pIRES GFP or left 
untreated for 48 or 72 hrs.  No pIRES-GFP expression was detected in the HEK-WT 
untransfected cells -C, brightfield image, A.  Transiently transfected HEK cells 
displayed positive expression of pIRES-GFP at 48 hrs post transfection panels B and 
D.  Positive expression was also observed at 72 hrs F, with absent signal in the non-
transfected control E. 
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4.3.12. Transient expression of SNAP-25 in HEK cells was greater when 
transfected with the construct lacking the fluorescent tag 
compared to that with the GFP tagged construct 
HEK cells were transiently transfected with either SNAP-25 pIRES-GFP or 
pcDNA3-SNAP25-WT (a kind gift from Prof. Herbert Gaisano, University of 
Toronto) or left untreated for 48 or 72 hrs, respectively.  Subsequently, the cells 
were lysed with SDS sample buffer and separated by SDS-PAGE and Western 
blotted for reactivity to an internal control α-actin and α-SNAP-25 SMI-81 
antibodies.  Greater expression was observed with the construct lacking the 
fluorescent tag compared to the GFP tagged construct at 72 hrs (Figure 4-19, 
72 hrs, lanes 1 vs. 3). 
            
Figure 4-19 Western blot of SNAP-25-WT expression at 48 and 72 hrs.   
HEK cells were transiently transfected with pcDNA3 encoding SNAP-25-WT pIRES 
GFP (lane 1) or SNAP-25-WT without the fluorescent tag (lane 3) or left untreated for 
48 or 72 hrs (lane 2) prior to lysis in SDS sample buffer.  Each sample 10 µl was 
separated by SDS-PAGE and Western blotted.  Membranes were probed with the 
following antibodies: α-actin and α-SNAP-25 SMI-81 antibodies. 
4.4. Discussion and conclusions 
Antibodies to human TRPV1 were generated by immunisation with a peptide 
synthesised to a selected amino acid sequence region of human TRPV1.  The 
immunised peptide (hTRPV1-A) shares 69% identity of amino acids with rat 
TRPV1, and 63% identity of amino acids with mouse TRPV1. 
Immunocytochemistry data revealed that these antibodies specifically detect 
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TRPV1 in a transiently over-expressed culture of HEK cells used as a screening 
assay (permeabilised, unpermeabilised and live cell staining); positive staining 
was blocked by competition with the control blocking peptide (100-fold molar 
excess) and no staining was observed in the non-transfected HEK-WT control 
cells.  Western blotting and immunocytochemistry data confirmed that detection 
with this antibody is dose-dependent and that antibody binding increases over 
time.  Unfortunately, α-TRPV1 polyclonal antibodies did not detect rat TRPV1 
when it was transiently transfected in HEK cells.  One of the main limitations of 
using HEK cells as the primary platform for this study is that they do not 
endogenously express SNAP-25, which is an essential requirement to 
investigate if antibodies conjugated to LC.HN.HCN/A are capable of cleaving its 
substrate.  To overcome this obstacle, HEK cells were transiently transfected 
with SNAP-25 using two different plasmids, a model over-expressing SNAP-25 
was established and may be utilised to screen potential BoNT-based bio-
therapeutics in vitro.  α-hTRPV1-A antibodies have now been characterised and 
may be utilised as a valuable tool to target BoNT-based therapeutics in the 
future or, alternatively, could be used for more elegant 
immunocytochemistry/immunohistochemistry studies. 
4.5. Future work 
One of the main limitations of these hTRPV1-A polyclonal antibodies is that they 
can only be investigated in a human TRPV1 expressing model; this, significantly 
limits their usefulness.  For antibodies to be used as a therapeutic targeting 
agent, they would ideally be firstly evaluated in a primary sensory neuronal cell 
culture model before moving to a suitable pre-clinical in vivo model.  Rabbits 
that were immunised produced an immune response to TRPV1-A-BSA, but 
were not reactive to rat TRPV1, suggestive of a lack of immunogenicity towards 
the TRPV1-B peptide as it shares 100 % identity to human and rat and would 
therefore be expected to detect both.  An immune response to this epitope 
would be advantageous, as it could have been evaluated in both rat and human 
models.  Interestingly, although the TRPV1-A peptide does not recognise rat 
TRPV1, it shares 100 % identity to guinea pig TRPV1.  Thus, it could be further 
investigated in guinea pig sensory neurons and, subsequently, in a guinea pig 
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pre-clinical pain model.    Although, guinea pigs would provide a model that 
would more closely mimic the human system, they generally have small litter 
sizes (1-4), longer gestation periods and require much larger housing than rats 
which limits their use for this study.  The TRPV1-B peptide is currently being 
resynthesized for immunisation, this would provide α-TRPV1 antibodies with 
reactivity to both human and rat which could be evaluated in the already 
established rat sensory neuron cultures and in vivo SNL model of neuropathic 
pain in rat (Chapter 3). 
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5. DEVELOPMENT OF SINGLE CHAIN ANTIBODIES FOR 
FUTURE TARGETING OF THE LC.HN.HCN/A TO TREAT 
CHRONIC PAIN 
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5.1. Background 
The primary purpose of producing antibodies against TRPV1, is that these 
could be used to target therapeutics specifically to sensory neurons.  Ideally, 
single chain antibodies would be generated as the genes encoding TRPV1 
recombinant antibodies could be gene ligated onto a modified BoNT therapeutic 
and could be expressed in large quantities for targeting.  An alternative 
targeting strategy would be to chemically conjugate the purified polyclonal 
antibodies onto the BoNT based therapeutic. 
5.1.1. Single chain antibodies as tools for targeting BoNT Zn2+-
dependent light chain proteases to sensory neurons 
In collaboration with Dr. Arman Rahman1 and Prof. John McCafferty2 of DCU1 
and Cambridge University2, 48 rabbit clones were isolated from the TRPV1-A 
rabbit library using phage display; these fall into 13 different groups based on 
the variability of their gene sequences.  Initially, RNA was extracted from rabbit 
spleen cells following immunization with the TRPV1-A peptide conjugated to 
BSA.  This RNA was reverse transcribed into cDNA and used as a template for 
building the rabbit antibody library.  The heavy and light chains were amplified 
using primers, specially designed at Cambridge University, and assembled into 
a single gene.  PCR reactions were carried out with selected primers to add 
restriction sites to facilitate cloning into the phagemid vector and to amplify the 
scFv DNA fragment.  The scFv ligated vector was then transformed into 
competent BL21 E.coli cells and grown before infecting with a helper phage; 
this produced recombinant phages displaying the TRPV1-A scFv fragments 
fused to the phage coat proteins.  Bio-panning was used to screen and enrich 
the antigen specific TRPV1-A clones.  The benefit of this approach is that the 
genes encoding these recombinant antibodies could be ligated onto that for a 
modified BoNT to target and deliver its light chain protease solely into sensory 
neurons. 
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5.1.2. Replacement of the binding domain of BoNTs with alternative 
moieties to allow therapeutic retargeting to sensory neurons 
Substituting the binding domain of BoNT with an antibody, protein or peptide 
targeting moiety could generate a novel biotherapeutic that is capable of being 
retargeted to a region it is not physiologically designed to reach; this would 
provide immense therapeutic potential.  Once the inserted domain binds to its 
new target, the HN domain may be able to facilitate translocation of the LC to 
the cytosol by its usual mechanism.  Evidence of BoNT retargeting to other cells 
was achieved when NGF was conjugated to the LHN/A; although lacking the 
binding domain, it cleaved SNAP-25 and blocked noradrenaline release from 
PC12 cells (Chaddock et al., 2000a).  Subsequently, wheat germ agglutinin was 
conjugated to the LHN/A; it was capable of targeting to both neuronal and non-
neuronal cells, cleaving SNAP-25 and inhibiting neurotransmitter release in 
cells that are not usually responsive to treatment (Chaddock et al., 2000b).  
Interestingly, LHN/A has been conjugated to a lectin isolated from Erythrina 
cristagalli to target nociceptive afferents.  Application of this novel conjugate 
blocked the release of substance P and glutamate from sensory cultured 
embryonic neurons (Duggan et al., 2002).  This study was further supported by 
in vivo electrophysiology of the spinal cord which revealed that direct exposure 
to 100 µl of LHN/A-ECL (4.5 µg/µl), reduced both C  and Aβ fibre evoked activity 
by ~ 32 and 12 % respectively, while Aδ activity was not affected suggesting 
that it predominantly acts on the presynaptic peripheral sensory afferent 
(Duggan et al., 2002).  The potential of this LHN/A lectin conjugate to alleviate 
pain was further investigated in a pre-clinical mouse acute model of thermal 
pain where intrathecal administration of the conjugated biotherapeutic alleviated 
latencies in response to the hot plate for at least 30 days post treatment 
(Chaddock et al., 2004).  Collectively, these exciting results prove that this 
strategy could be used to retarget BoNTs for new indications. 
5.2. Aims and objectives 
 To develop single chain antibodies that could be used to retarget BoNT-
based therapeutics to sensory neurons. 
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 To characterise a panel of rabbit α-TRPV1-A single chain antibodies. 
 To conjugate α-TRPV1-A purified polyclonal antibodies to the 
LC.HN.HCN/A (comprised of the light chain, translocation domain and N-
terminal heavy chain of BoNT/A, but lacking the binding domain). 
5.3. Results 
5.3.1. Rabbit α-TRPV1-A scFv clones isolated by panning are reactive to 
TRPV1-A  
All the panel of rabbit α-TRPV1-A scFv clones, isolated by panning by Dr. 
Arman Rahman, proved to be reactive with TRPV1-A-BSA but not BSA (Figure 
5-1). 
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Figure 5-1 Reactivities of the isolated phage scFv clones. 
Individual colonies were picked into 96 well plates in 150 µl medium (2TY plus glucose 
and kanamycin).  After 24 hrs, plates were hedgehoged into new 96 well plates 
containing complete ZY medium and cultured for additional 20 hrs at 300C. Plates were 
centrifuged at 3200 g for 15 minutes, and the supernatant tested by ELISA onto a pre 
coated α-TRPV1-A antigen 96-well Nunc Maxisorb plate.  The plate was blocked with 
BSA to eliminate BSA signal from the immunised carrier protein. 
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5.3.2. α-TRPV1-A scFv clones yielded high reactivities to hTRPV1-A 
α-TRPV1-A rabbit scFv clones were analysed by direct ELISA (as described in 
the Methods section) against TRPV1-A-KLH (Figure 5-2).  High absorbance 
values at 450 nm were obtained for supernatant (A) and periprep (B) rabbit 
scFv clones screened against the hTRPV1-A-KLH coated antigen plates (Figure 
5-2 A and B).  The panel of clones tested (supernatant or periprep) lacked 
reactivity to BSA (Figure 5-2 C and D). 
 
Figure 5-2 Reactivities of single chain α-hTRPV1 rabbit and human antibodies to 
the hTRPV1-A-KLH and BSA.   
scFv TRPV1-A rabbit antibodies present in either the supernatant A and C) or periprep 
B and D) were analysed by direct ELISA to determine their reactivities to either TRPV1 
(A and B) or to BSA (C and D).  For the supernatant ELISA, 50 µl of the overnight 
culture for each clone were analysed.  For the periprep ELISA, 10 µl of crude 
periplasmic preparation was dissolved in 40 µl PBS and processed as described in the 
methods ELISA section 2.2.2.3.  The following antibodies were employed; mouse 
monoclonal α-FLAG® 1O (1/500 dilution), followed by, α-mouse HRP 2O (1:5000 
dilution).    
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5.3.3.  Free TRPV1 peptide competed with the α-hTRPV1-A scFv rabbit    
clones 
A direct ELISA was performed to determine what dilution of each scFv would 
give an absorbance of 1 at 450 nm (Figure 5-3 A); these dilutions were 
subsequently used for the competitive ELISA in (Figure 5-3 B).  Results 
revealed that free TRPV1-A peptide competes with each of the scFv TRPV1-A 
rabbit clones analysed giving ~ IC50 values of 2.66, 1.33, 0.26, 10.64, 2.66, 1.33 
and 13.33 µM for clones 9, 16, 17, 59, 60, 61 and 63, respectively, Figure 5-3 B.  
Clones 17 and 63 had the lowest and highest IC50 values.  These results are 
presented in Table 5-1 below. 
 
Figure 5-3 Direct and competitive ELISA of the scFv rabbit clones. 
Plates were coated with the TRPV1-A-KLH peptide, 10 µg/mL overnight at 4OC; 20 mL 
cultures were grown for each clone and the crude lysates analysed by direct and 
competitive ELISA.  For the competitive ELISA, increasing concentrations of the control 
TRPV1-A non-conjugated peptide were incubated with the clone dilution that gave a 
direct ELISA A450 of 1.  The following antibodies were employed; mouse monoclonal 
α-FLAG® 1O (1/500 dilution), followed by, α-mouse HRP 2O (1:5000 dilution).     
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Clones ~ IC50 values (µg/mL) IC50 values (µM) 
9 0.2 2.66 
16 0.1 1.33 
17 0.02 0.26 
59 0.8 10.64 
60 0.2 2.66 
61 0.1 1.33 
63 1 13.3 
Table 5-1 Approximate IC50 values for rabbit TRPV1-A scFv clones 
5.3.4. α-TRPV1-A scFv clones were expressed in E. coli and Western 
blotting confirmed the presence of the FLAG® tag 
hTRPV1-A rabbit scFv clones were classified into 13 groups based on the 
variability of their gene sequences.  All of the rabbit clones were seeded onto 
individual 2TY agar plates containing glucose and kanamycin and grown 
overnight at 37OC.  From each of these plates, a single colony was picked and 
seeded into a 5 mL starter culture (2TY medium, 2 % glucose, 100 µg/mL 
kanamycin) and grown overnight at 30OC.  A 1:1000 dilution of each of these 
starter cultures was inoculated into 2TY medium containing 2 % glucose and 
100 µg/mL of kanamycin.  This was grown until an A600 nm of 0.6-0.8 was 
reached, temperature was then reduced to 22OC and 1 mM of IPTG added to 
induce the culture.  After growing overnight for a further 16-20 hrs, cells were 
lysed and the expressed protein was purified by IMAC as described in the 
Materials and Methods section.  Samples were collected from each of the 
stages of the IMAC process, separated by SDS-PAGE and protein stained; 
results confirmed that the product separated was of the correct size ~ 30 K 
(Figure 5-4 A).  Western blot detected the presence of the FLAG® tag (this is an 
8-amino acid peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) which was 
incorporated into the recombinant antibody production to facilitate screening) in 
the eluates (Figure 5-4 B). 
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Figure 5-4 Protein expression and IMAC purification of single chain rabbit TRPV1 
clone number 9.   
Aliquots from each of the IMAC samples were collected and separated by SDS-PAGE 
followed by either Coomassie staining (A) or Western blotting for the FLAG® tag (B).  
Clone 9: 1= Precision plus markers; 2 = flow through, 1:10 dilution; 3 = wash 1, 
undiluted; 4 = wash 8, undiluted; 5-10 = elutes, undiluted, 11 = flow through, 1:20 
dilution, 12 = wash 1, 1:5 dilution, 13 = wash 8, 1:5 dilution, 14-19 = elutes, 1:5 dilution.  
1
o
 antibody- mouse α FLAG® antibody 1:500; 2
o
 antibody- donkey α mouse HRP 
1:5000 dilution.  Further details regarding the expression and purification of scFv 
antibodies can be found in sections 2.2.2.7 and 2.2.2.9.1. 
5.3.5. No binding of the α-hTRPV1-A rabbit scFv crude lysates to a 
protein at 95 K was observed in TRPV1 transiently over-
expressed HEK cells   
Almost all (47/48) of the hTRPV1 scFv rabbit clones were screened for binding 
to human TRPV1.  Each scFv was expressed in E. coli (50 mL cultures) from 
which crude lysates (5 mL) were prepared and shown by densitometric analysis 
of Western blotting (Figure 5-5) by Image J software to contain between 20 and 
50 µg of over-expressed scFv.  HEK cells over-expressing human TRPV1 and 
WT untransfected control cells were separated by SDS-PAGE; membranes 
were subsequently incubated with scFv lysates overnight at 4OC.    
Unfortunately, none of the scFv clones tested to date were found to bind to 
TRPV1 at 95 K, despite the detection of over-expressed TRPV1 by the serum 
polyclonal antibody used as a positive control.  Some scFv clones 
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demonstrated considerable binding to endogenous HEK proteins; however, 
these were present in both the negative and positive controls and migrated at 
sizes not representative of TRPV1 (Figure 5-6). 
 
Figure 5-5 Protein concentration (µg/lysate) of the rabbit clonal lysates.  
A single colony for each clone was selected and seeded into a 5 mL starter culture 
(2TY medium, 2 % glucose, 100 µg/mL kanamycin) and grown overnight at 30OC.  A 
1:1000 dilution of each of these starter cultures was inoculated into 2TY medium 
containing 2 % glucose and 100 µg/mL of kanamycin.  This was grown until an A600 
nm of 0.6-0.8 was reached, temperature was then reduced to 22OC and 1 mM of IPTG 
added to induce the culture. Subsequently, scFv clonal lysates were separated by 
SDS-PAGE and Western blotted for the presence of the FLAG® tag.  Western blots 
were analysed by densitometric analysis using image J software and graphed.  
Antibodies employed include; 1
o
- scFv clonal lysates; 2
o
 -mouse α-FLAG® antibody 
(1:500), followed by α-mouse AP (1:10000).  Further details regarding the expression 
of scFv TRPV1 clones can be found in section 2.2.2.7 of the Materials and Methods 
chapter. 
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Figure 5-6 Specificity of the rabbit α-hTRPV1-A purified single chain antibodies 
to hTRPV1. 
HEK cells were transiently transfected with pcDNA3 encoding either human TRPV1 or 
left untreated for 24 hrs prior to lysis in SDS sample buffer.  Each sample (10 µl) was 
separated by SDS-PAGE and Western blotted.  Membranes were incubated overnight 
at 4OC with the α-hTRPV1 scFv clonal lysates or with the control DAKA polyclonal 
serum.  Antibodies employed include; 1
o
- scFv clonal lysates; 2
o
 -mouse α-FLAG® 
antibody (1:500), followed by α-mouse AP (1:10000).  Method details for screening the 
panel of scFv clones can be found in section 2.2.2.11 of the Materials and Methods 
chapter. 
5.3.6. LC.HN.HCN/A was expressed, purified and activated by nicking 
with thrombin 
LC.HN.HCN/A was expressed and purified following standard laboratory 
established protocols which yielded a main protein band of 125 K on 
SDS/PAGE.  Its purity was confirmed by the lack of contaminants.  Incubation 
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with thrombin completely converted the single chain (SC) to the dichain (DC), 
confirmed by the expected HC and LC sizes after separation by SDS-PAGE in 
the presence of reducing agent, followed by Coomassie staining (Figure 5-7).   
 
 
 
 
 
 
Figure 5-7 Expression, purification and activation of the LC.HN.HCN/A. 
5.3.7. Attempted chemical conjugation of the LC.HN.HCN/A hTRPV1 
polyclonal antibodies did not reveal the expected size for the 
conjugated product 
As the single chain antibodies were unable to detect hTRPV1 in the over-
expressed cell culture model, there was a shift of focus to the purified polyclonal 
antibodies.  Thus, it was decided to chemically conjugate these to the 
LC.HN.HCN/A (comprised of the light chain, translocation domain and N-terminal 
heavy chain of BoNT/A, but lacking the binding domain).  Its conjugation to the 
Fc portion of α-hTRPV1 IgGs was attempted by oxidation of the carbohydrates 
present in the Fc region with periodic acid.  This reaction cleaves bonds 
positioned between adjacent carbon atoms containing hydroxyl groups, 
resulting in the formation of two aldehyde groups that are reactive to both amine 
and hydrazide cross linking products.  As the sulfhydryls present in the 
LC.HN.HCN/A may not be accessible, Trauts reagent (2-iminothiolane) (20, 40, 
50 and 100-fold molar excess) was employed to introduce free sulfhydryls into 
the LC.HN.HCN/A by reacting with primary amines.  Ellman’s reaction was used 
to determine if sulfhydryl groups had been introduced into the LC.HN.HCN/A; 
results revealed an introduction of cysteines into the LC.HN.HCN/A.  Following 
The buffer exchanged LC.HN.HCN/A sample was 
incubated with or without thrombin (1 mg toxin 
per unit of thrombin, for 1 hr at 22oC) to activate 
the toxin.   Subsequently, samples were 
separated by SDS-PAGE in the presence or 
absence of reducing agent, followed by 
Coomassie staining.  Lanes 3 (- thrombin) and 4 
(+ thrombin).  In the presence of thrombin under 
reducing conditions (lane 4, + DTT), the SC was 
successfully converted to the DC active form.  
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confirmation that sulfhydryls had been introduced, the LC.HN.HCN/A was 
subsequently incubated with a hetero-bifunctional water-soluble, crosslinker 
namely 3, 3’-N-[e-maleimidocaproic acid] hydrazide trifluroacetic acid salt 
(EMCH- 10 and 20-fold molar excesses) containing a sulfhydryl reactive 
maleimide group and a functional carbonyl hydrazide group at either ends of a 
6-carbon spacer the LC.HN.HCN/A. The maleimide group present in the linker 
reacts with sulfhydryl groups and the hydrazide group reacts with oxidised 
carbohydrates; together these reactions should form the α-hTRPV1-
LC.HN.HCN/A conjugate by the formation of hydrazone bonds (Figure 5-8).  
Ellman’s reaction revealed that incubation with the EMCH linker decreased the 
number of cysteines that were initially introduced by Traut’s, suggesting that 
cysteines were being modified by the linker.  Finally, the oxidised antibody was 
incubated with the Trauts and EMCH reacted LH.HN.HCN/A in a range of molar 
ratios of antibody to toxin including 2, 3 and 5:1, for varying times including 2 
hrs at room temperature, and 4 and 16 hrs at 4oC.  To date, attempts of this 
conjugation have been unsuccessful, as the conjugated produced size was not 
observed when separated by SDS-PAGE (Figure 5-9 A).   
            
Figure 5-8 Schematic of the chemical conjugation strategy to join the α-hTRPV1 
antibodies to the LC.HN.HCN/A.   
The Fc portion of the antibody is reacted with periodate to oxidise the carbohydrates 
present and to produce reactive aldehyde groups.  The LC.HN.HCN/A is reacted with 
Traut’s reagent to introduce free sulfhydryls; this is subsequently reacted with the Mal-
linker-NHNH2 which contains a sulfhydryl reactive maleimide group and a carbonyl 
reactive hydrazide group at either ends of a 6 carbon spacer arm.  The oxidised 
antibody is incubated with the reactive LC.HN.HCN/A for the required time to create the 
LC.HN.HCN/A antibody conjugate.  Figure prepared by Dr. Om Prakash. 
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5.3.8. Application of the LC.HN.HCN/A-antibody conjugated mixture onto 
A549 cells cleaved SNAP-25, presumably due to the free toxin 
Samples from each of the conjugation steps (described above) were collected 
and subsequently separated by SDS-PAGE and stained by Coomassie.  The 
expected conjugated product size was not visualised (Figure 5-9 A).  
Nevertheless, the antibody-LC.HN.HCN/A mixture from the final step was applied 
to A549 cells which express SNAP-25; its cleavage was observed, however, 
this was presumably due to the presence of the free toxin (Figure 5-9 B). 
 
Figure 5-9 Unsuccessful chemical conjugation of the LC.HN.HCN/A to α-hTRPV1-A 
IgGs. 
Samples (2 µg) from each step of the conjugation process were separated by SDS-
PAGE, followed by Coomassie staining.  1. Nicked toxin (LC.HN.HCN/A sample was 
incubated with thrombin (1 mg toxin per unit of thrombin, for 1 hr at 22oC) to activate 
the toxin by converting the SC to the DC active form), 2. Toxin + EMCH linker, 3.  
Antibody (Ab) concentrated, 4.  Ab oxidised, 5.  The final conjugated mixture- Ab + 
Toxin (Figure 4-10 A).  The final product (lane 5) was applied to A549 cells, in varying 
concentrations and incubation times.  Following incubation, the cells were lysed, 
separated by SDS-PAGE and Western blotted for SNAP-25 using the SMI-81 1o 
antibody.  Further details regarding the chemical conjugation method can be found in 
section 2.2.2.10 of the Materials and Methods chapter. 
5.4. Discussion and conclusions 
Characterisation of the polyclonal α-TRPV1-A antibodies in Chapter 3 confirmed 
its specificity for hTRPV1.  However, recombinantly-produced scFv antibodies 
would be more useful as they could be gene ligated onto the LC.HN.HCN/A to 
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direct its Zn2+-dependent light chain proteases into sensory neurons.  Single 
chain antibodies are smaller in size (~ 30 K) and would have greater 
accessibility to their target epitope.  Encouragingly, the scFv antibodies 
analysed were highly reactive to hTRPV1-A, and yielded low direct ELISA 
absorbance values to the immunised carrier protein BSA.  Competitive ELISA 
revealed that free TRPV1-A peptide competes with ~ IC50 values of 2.66, 1.33, 
0.26, 10.64, 2.66, 1.33 and 13.33 µM for clones 9, 16, 17, 59, 60, 61 and 63, 
respectively Figure 4-4 B.  When the rabbit scFv clones were screened in the 
established HEK cell model over-expressing human TRPV1, no band was 
detected at the expected size for TRPV1 (~ 95 K), although, TRPV1 was 
detected by the polyclonal DAKA α-TRPV1-A antibody at the correct size.  
Given the lack of reactivity to human TRPV1 with the panel of scFv clones 
isolated, it was decided to chemically conjugate the purified polyclonal antibody 
to the LC.HN.HCN/A.  Review of the literature verified that chemical conjugation 
strategies have been used to conjugate a variety of agents to the LC.HN/A.  
Samples from the conjugation process were analysed by SDS-PAGE (2 µg of 
each to verify if the product was of the correct size), reaction with Ellmans (to 
determine if sulfhydryls had been introduced into the LC.HN.HCN/A by Traut’s 
reagent and if these had been modified by the EMCH linker) and by Schiff 
reaction (to confirm antibody oxidation).  Although, oxidation, introduction and 
modification of sulfhydryls were all confirmed; when the oxidised antibody and 
reacted with the LC.HN.HCN/A, no conjugated product was separated by SDS-
PAGE.  Perhaps, if more starting materials were used, the conjugated product 
might be observed. 
5.5. Future work 
Although polyclonal antibodies proved promising, the chemical conjugation 
strategy was unsuccessful to date; this would require further optimisation.  
Additionally, scFv clones isolated did not bind to human TRPV1 at 95 K; to 
overcome this obstacle, the scFv library would need to repanned with greater 
stringency to isolate specific clones; however, these would again only recognise 
human TRPV1.  Currently, both TRPV1-A and B peptides are being 
resynthesised.  scFv clones isolated from the TRPV1-B library, would be 
110 
 
reactive to both human and rat.  This would be advantageous for specific 
targeting to sensory neurons as it could be evaluated in existing sensory 
neuronal cultures and in an already established in vivo model.  Additionally, 
assays (Western blotting and immunocytochemistry) have been established to 
allow fast screening and characterisation of future clones.  
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